UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM ~~10-Q/A~~

~~(Amendment No. 1)~~10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~September 30, 2020

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission File Number: 000-24249

Interpace Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

22-2919486

(State or other jurisdiction of

Incorporation or organization)

(I.R.S. Employer

Identification No.)

Morris Corporate Center 1, Building C

300 Interpace Parkway, Parsippany, NJ 07054

(Address of principal executive offices and zip code)

(855) 776-6419

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	IDXG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [X]		Smaller reporting company [X]
		Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class				Shares Outstanding ~~June 12, 2020~~January 8, 2021
	Common Stock, par value $0.01 per share		~~4,036,595~~		4,055,593

INTERPACE BIOSICENCES, INC.

FORM ~~10-Q/A~~10-Q FOR PERIOD ENDED ~~MARCH 31,~~SEPTEMBER 30, 2020

TABLE OF CONTENTS

		Page No.

	EXPLANATORY NOTE	3

	PART I - FINANCIAL INFORMATION

Item 1.	Unaudited Interim Condensed Consolidated Financial Statements

	~~Condensed Consolidated Balance Sheets at March 31, 2020 (unaudited) and December 31, 2019~~	4

	Condensed Consolidated Balance Sheets at September 30, 2020 (unaudited) and December 31, 2019	4

	Condensed Consolidated Statements of Operations for the three- ~~month~~and nine-month periods ended ~~March 31,~~September 30, 2020 and 2019 (unaudited)	5

	Condensed Consolidated Statements of Stockholders’ Equity for the three- ~~month~~and nine-month periods ended ~~March31,~~September 30, 2020 and 2019 (unaudited)	6

	Condensed Consolidated Statements of Cash Flows for the ~~three-month~~nine-month periods ended ~~March 31,~~September 30, 2020 and 2019 (unaudited)	7

	Notes to Unaudited Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3326

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4340

Item 4.	Controls and Procedures	4340

	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	4341

Item 1A.	Risk Factors	4441

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4441

Item 3.	Defaults Upon Senior Securities	4441

Item 4.	Mine Safety Disclosures	4441

Item 5.	Other Information	4441

Item 6.	Exhibits	4542

Signatures		4643

EXPLANATORY NOTE

On ~~March 25,~~November 17, 2020, the ~~U.S.~~Company filed a Form 12b-25 notifying the Securities and Exchange Commission ~~(the “SEC”~~(“SEC”) ~~issued an order Release No. 34-88465 (the “Order”) pursuant~~of its inability to file its authority under Section 36 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) granting exemptions from certain provisions of that Act and the rules thereunder related to the reporting and proxy delivery requirements for certain public companies. Interpace Biosciences, Inc. (the “Company”) is filing this Quarterly Report on Form 10-Q for the ~~quarter~~quarterly period ended ~~March 31,~~September 30, 2020 ~~in reliance~~ on ~~the Order, permitting~~ a ~~delay in filing due to circumstances related to COVID-19.~~timely basis. The Company ~~filed, on May 15, 2020, a Current Report on Form 8-K (the “May 15~~^th ~~8-K”) indicating~~was evaluating whether there has been an impairment of the carrying value of its ~~intention~~Barrett intangible asset and whether adjustments to ~~rely on~~recorded amortization expense may be required. The Barrett intangible asset amounted to $18.4 million and was originally recorded in 2014 when the ~~Order. As stated in the May 15~~^th ~~8-K,~~Company’s predecessor, PDI, Inc., acquired RedPath Integrated Pathology, Inc. and relates to the Company ~~required additional time~~propriety test known as BarreGEN^®, an esophageal cancer risk classifier for Barrett’s Esophagus. Due to ~~finalize this report due~~the extended coordination, evaluation and communication needed to ~~circumstances related~~conduct the impairment analysis and assessment of amortization expense, the analysis could not be completed on a timely basis to ~~COVID-19,~~permit the ~~disease caused~~Company to file its Form 10-Q by November 16, 2020.

On December 7, 2020, the ~~coronavirus. The effects of COVID-19 have limited~~Company’s management conferred with the ~~abilities~~Audit Committee of the Company’s ~~employees to conduct normal business activities. This, in turn, delayed~~Board of Directors and concluded that (1) a non-cash impairment charge for its Barrett intangible asset of approximately $11.6 million should have been recorded during the Company’s ~~ability~~2016 fiscal year; (2) the Company should have initiated amortization of its Barrett intangible asset in fiscal 2014 and therefore each of fiscal years 2014, 2015, 2016, 2017, 2018, and 2019 and the first two quarters of fiscal 2020 require adjustment to ~~prepare this report.~~

~~This Amendment No. 1~~recorded amortization expense of approximately $6 million in the aggregate; (3) the consolidated financial statements contained in the Company’s Annual Reports on Form ~~10-Q/A (this Amendment) amends~~10-K for the ~~Company’s Report~~years ended December 31, 2014, 2015, 2016, 2017, 2018, and 2019, as well as the consolidated financial statements contained in the Quarterly Reports on Form 10-Q for the ~~quarter ended March 31, 2020,~~each quarterly period within those fiscal years as ~~amended, (the “Original Filing”) and is being filed to show~~well as the impact in such quarter of intangible asset amortization and impairment expense for its Barrett’s and Thyroid assets which began in 2014. Subsequent to the issuance of its consolidated financial statements for the year ended December 31, 2019 and the quartersquarterly periods ended March 31, 2020 and June 30, 2020, should no longer be relied upon; and (4) Management’s Report on Internal Control Over Financial Reporting and the ~~Company determined that amortization should have commenced upon acquisition~~Evaluation of ~~those assets as opposed to the Company’s previously disclosed policy of beginning asset amortization when the product was launched~~Disclosure Controls and ~~generating revenue. The impact~~Procedures included in Item 9A of the ~~additional amortization expense for each of the quarters ended March 31, 2020 and March 31,~~ 2019 was approximately $0.1 million. The impact of the other immaterial adjustments for the quarters ended March 31, 2020 and March 31, 2019 was $0.1 million in expense and $0.2 million in a credit to expense, respectivelyForm 10-K should no longer be relied upon.

A description of these adjustments and a summary showing their effect on the restated consolidated statements of operations is provided in Note 1 to the consolidated financial statements. In addition to the errors described above, the restated financial statements also include adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years’ financial statements.

The Company is filing this report in order to amend certain information in Items 1, 2 and 4 of Part I to reflect the restatement of the March 31, 2020 and 2019 unaudited interim consolidated statements of operations and Notes 1,3,5 and 9 to the consolidated financial statements attached hereto solely to the extent necessary to reflect the adjustments described herein; and the principal executive officer and principal financial officer certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Except for the foregoing items, no other information in the Original Filing is revised by this Amendment.

PART I. FINANCIAL INFORMATION

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	As Restated			As Restated
	March 31,			December 31,			September 30,			December 31,
	2020			2019			2020			2019
		(unaudited)					(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	13,370		$	2,321		$	5,308		$	2,321
Accounts receivable, net of allowance for doubtful accounts of $275 and $25, respectively		9,799			10,338			8,463			10,338
Other current assets		4,976			3,851			3,861			3,851
Total current assets		28,145			16,510			17,632			16,510
Property and equipment, net		6,610			6,814			7,332			6,814
Other intangible assets, net		14,734			15,849			12,504			15,849
Goodwill		8,433			8,433			8,433			8,433
Operating lease right of use assets		2,811			3,892			4,758			3,892
Other long-term assets		42			42			42			42
Total assets	$	60,775		$	51,540		$	50,701		$	51,540

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	4,456		$	4,709		$	3,390		$	4,709
Accrued salary and bonus		1,865			2,341			1,314			2,341
Other accrued expenses		8,639			9,476			10,131			9,476
Current liabilities from discontinued operations		766			766			766			766
Total current liabilities		15,726			17,292			15,601			17,292
Contingent consideration		2,264			2,391			2,130			2,391
Operating lease liabilities, net of current portion		1,384			2,591			3,746			2,591
Line of credit		1,200			3,000			-			3,000
Other long-term liabilities		4,563			4,573			4,486			4,573
Total liabilities		25,137			29,847			25,963			29,847

Commitments and contingencies (Note 8)

Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 Series A shares issued and outstanding		-			26,172			-			26,172
47,000 Series B shares issued and outstanding		46,536			-			46,536			-

Stockholders’ equity:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,055,454 and 3,932,370 shares issued, respectively; 4,043,673 and 3,920,589 shares outstanding, respectively		402			393
Common stock, $.01 par value; 100,000,000 shares authorized; 4,060,454 and 3,932,370 shares issued, respectively; 4,041,595 and 3,920,589 shares outstanding, respectively								402			393
Additional paid-in capital		182,580			182,514			183,543			182,514
Accumulated deficit		(192,159	)		(185,665	)		(203,973	)		(185,665	)
Treasury stock, at cost (11,781 and 11,781 shares, respectively)		(1,721	)		(1,721	)
Treasury stock, at cost (18,859 and 11,781 shares, respectively)								(1,770	)		(1,721	)
Total stockholders’ equity		(10,898	)		(4,479	)		(21,798	)		(4,479	)
Total liabilities and stockholders’ equity	$	14,239		$	25,368		$	4,165		$	25,368

Total liabilities, preferred stock and stockholders’ equity	$	60,775		$	51,540		$	50,701		$	51,540

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except for per share data)

	As Restated
	Three Months Ended March 31,						Three Months Ended						Nine Months Ended
	2020			2019			September 30,						September 30,
							2020			2019			2020			2019

Revenue, net	$	9,059		$	6,010		$	8,248		$	7,725		$	22,752		$	20,005
Cost of revenue (excluding amortization of $1,115 and $897, respectively)		6,113			2,622
Cost of revenue (excluding amortization of $1,115 and $1,079, for the three months and $3,346 and $2,874 for the nine months, respectively)								5,194			4,835			15,156			10,489
Gross profit		2,946			3,388			3,054			2,890			7,596			9,516
Operating expenses:
Sales and marketing		2,481			2,411			2,699			2,757			6,776			8,127
Research and development		809			528			763			857			2,123			2,032
General and administrative		4,893			2,735			4,482			4,492			13,481			9,613
Acquisition related expense								-			838			-			2,534
Acquisition related amortization expense		1,115			897			1,115			1,079			3,346			2,874
Total operating expenses		9,298			6,571
								9,059			10,023			25,726			25,180

Operating loss		(6,352	)		(3,183	)		(6,005	)		(7,133	)		(18,130	)		(15,664	)
Interest accretion		(109	)		(129	)		(138	)		(111	)		(414	)		(331	)
Other income (expense), net		47			48
Other (expense) income, net								(12	)		(135	)		473			(12	)
Loss from continuing operations before tax		(6,414	)		(3,264	)		(6,155	)		(7,379	)		(18,071	)		(16,007	)
Provision for income taxes		15			5			14			9			43			19
Loss from continuing operations, net of tax		(6,429	)		(3,269	)		(6,169	)		(7,388	)		(18,114	)		(16,026	)

Loss from discontinued operations, net of tax		(65	)		(57	)		(65	)		(58	)		(194	)		(51	)

Net loss		(6,494	)		(3,326	)		(6,234	)		(7,446	)		(18,308	)		(16,077	)

Less adjustment for preferred stock deemed dividend		(3,033	)		-			-			-			(3,033	)		-

Less dividends on preferred stock								-			(75	)		-			(75	)
Net loss attributable to common stockholders	$	(9,527	)	$	(3,326	)	$	(6,234	)	$	(7,521	)	$	(21,341	)	$	(16,152	)

Basic and diluted loss per share of common stock:
From continuing operations	$	(2.37	)	$	(0.93	)	$	(1.53	)	$	(1.95	)	$	(5.25	)	$	(4.34	)
From discontinued operations		(0.01	)		(0.01	)		(0.01	)		(0.02	)		(0.05	)		(0.01	)
Net loss per basic and diluted share of common stock	$	(2.38	)	$	(0.94	)	$	(1.54	)	$	(1.97	)	$	(5.30	)	$	(4.35	)
Weighted average number of common shares and common share equivalents outstanding:
Basic		4,004			3,515			4,038			3,820			4,025			3,717
Diluted		4,004			3,515			4,038			3,820			4,025			3,717

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands)

As Restated As Restated
For The Three Months Ended For The Three Months Ended
March 31, 2020 March 31, 2019
Shares Amount Shares Amount
Common stock:
Balance at January 1 3,932 $ 393 2,877 $ 287
Common stock issued 37 1 9 1
Restricted stock issued 6 - - -
Common stock issued through market sales 80 8 - -
Common stock issued through offerings - - 933 94
Balance at March 31 4,055 402 3,819 382
Treasury stock:
Balance at January 1 12 (1,721 ) 7 (1,680 )
Treasury stock purchased - - 3 (32 )
Balance at March 31 12 (1,721 ) 10 (1,712 )
Additional paid-in capital:
Balance at January 1 182,514 175,820
Common stock issued through offerings, net of expenses - 5,868
Extinguishment of Series A Shares (828 ) -
Beneficial Conversion Feature in connection with Series B Issuance 2,205 -
Amortization of Beneficial Conversion Feature (2,205 ) -
Common stock issued through market sales 476 -
Stock-based compensation expense 418 266
Balance at March 31 182,580 181,954
Accumulated deficit:
Balance at January 1 (185,665 ) (158,981 )
Net loss (6,494 ) (3,326 )
Adoption of ASC 842 - 55
Balance at March 31 (192,159 ) (162,252 )

Total stockholders’ equity $ (10,898 ) $ 18,372
For The Nine Months Ended For The Nine Months Ended
September 30, 2020 September 30, 2019
Shares Amount Shares Amount
Common stock:
Balance at January 1 3,932 $ 393 2,877 $ 287
Common stock issued 37 1 9 1
Restricted stock issued 6 - - -
Common stock issued through market sales 80 8 - -
Common stock issued through offerings - - 933 94
Balance at March 31 4,055 402 3,819 382
Common stock issued - - 10 1
Balance at June 30 4,055 402 3,829 383
Common stock issued 5 - - -
Balance at September 30 4,060 402 3,829 383
Treasury stock:
Balance at January 1 12 (1,721 ) 7 (1,680 )
Treasury stock purchased - - 3 (32 )
Balance at March 31 12 (1,721 ) 10 (1,712 )
Treasury stock purchased 7 (49 ) - -
Balance at June 30 19 (1,770 ) 10 (1,712 )
Treasury stock purchased - - - -
Balance at September 30 19 (1,770 ) 10 (1,712 )
Additional paid-in capital:
Balance at January 1 182,514 175,820
Common stock issued through offerings, net of expenses - 5,868
Extinguishment of Series A Shares (828 ) -
Beneficial Conversion Feature in connection with Series B Issuance 2,205 -
Amortization of Beneficial Conversion Feature (2,205 ) -
Common stock issued through market sales 476 -
Stock-based compensation expense 418 266
Balance at March 31 182,580 181,954
Common Stock issued - 72
Stock-based compensation expense 400 205
Balance at June 30 182,980 182,231
Dividends accrued - (75 )
Stock-based compensation expense 563 205
Balance at September 30 183,543 182,361
Accumulated deficit:
Balance at January 1 (185,665 ) (158,981 )
Net loss (6,494 ) (3,326 )
Adoption of ASC 842 - 55
Balance at March 31 (192,159 ) (162,252 )
Net loss (5,580 ) (5,304 )
Balance at June 30 (197,739 ) (167,556 )
Net loss (6,234 ) (7,446 )
Balance at September 30 (203,973 ) (175,002 )

Total stockholders’ equity $ (21,798 ) $ 6,030

The accompanying notes are an integral part of these condensed consolidated financial statements.
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)

As Restated
For The Three Months Ended March 31, For The Nine Months Ended September 30,
2020 2019 2020 2019

Cash Flows From Operating Activities
Net loss $ (6,494 ) $ (3,326 ) $ (18,308 ) $ (16,077 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 1,319 957 4,102 3,164
Interest accretion 109 129 414 331
Reversal of 2019 bonus accrual (1,156 ) -
Mark to market on warrants (26 ) (3 ) (62 ) (35 )
Stock-based compensation 418 538 1,381 1,246
Bad debt expense 250 - 250 499
Other gains and expenses, net - 18 - 18
Other changes in operating assets and liabilities:
Decrease (increase) in accounts receivable 289 (1,738 ) 1,625 (1,986 )
(Increase) decrease in other current assets (1,125 ) 11
(Decrease) increase in accounts payable (253 ) 93
(Decrease) increase in accrued salaries and bonus (476 ) 205
(Decrease) increase in accrued liabilities (1,149 ) 99
Increase in long-term liabilities 16 57
Increase in other current assets (898 ) (417 )
Increase in long-term assets - (11 )
Decrease in accounts payable (1,319 ) (766 )
Increase in accrued salaries and bonus 129 108
Increase in accrued liabilities 1,472 924
(Decrease) increase in long-term liabilities (25 ) 446
Net cash used in operating activities (7,122 ) (2,960 ) (12,395 ) (12,556 )

Cash Flows From Investing Activity
Acquisition of Biopharma, net of expenses - (13,829 )
Purchase of property and equipment - (12 ) (1,275 ) (105 )
Sale of property and equipment - 13 - 13
Net cash provided by investing activity - 1
Net cash used in investing activities (1,275 ) (13,921 )

Cash Flows From Financing Activities
Issuance of common stock, net of expenses 434 6,015 434 5,962
Payments on Line of Credit (1,800 ) -
Issuance of preferred shares, net of expenses - 13,087
(Payments) borrowings on Line of Credit, net (3,000 ) 3,750
Issuance of Series B preferred stock, net of expenses 19,537 - 19,223 -
Cash paid for repurchase of restricted shares - (32 )
Net cash provided by financing activities 18,171 6,015 16,657 22,767

Net increase in cash and cash equivalents 11,049 3,056
Net increase (decrease) in cash and cash equivalents 2,987 (3,710 )
Cash and cash equivalents – beginning 2,321 6,068 2,321 6,068
Cash and cash equivalents – ending $ 13,370 $ 9,124 $ 5,308 $ 2,358

The accompanying notes are an integral part of these condensed consolidated financial statements.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
1. OVERVIEW

Nature of Business

~~The Company~~Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial ~~programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.~~programs.

Impact of COVID-19 pandemic

We have taken what we believe are ~~all~~ necessary precautions to safeguard our employees from the Coronavirus (COVID-19) pandemic. We ~~are following~~continue to follow the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local ~~restrictions.~~authorities. The majority of our employees who do not work in a lab setting are currently ~~on a telecommunication work arrangement and have generally been~~ able to successfully work remotely. While a number of employees were furloughed most have returned to work. Our labs require in-person staffing and ~~as of the date of this report,~~ we have been able to ~~successfully~~continue to operate our labs, minimizing infection risk to lab staff through a combination of social distancing and ~~protective equipment. Our employees in the lab are wearing what we believe is~~ appropriate protective ~~gear.~~equipment. There can be no assurance, however, that key employees will not become ill or that we will able to continue to operate our ~~labs. We have furloughed a number of employees as a result of reductions in customer demand.~~labs successfully.

The ~~extent to which~~continuing impact that the COVID-19 pandemic ~~impacts~~will have on our operations, ~~is dependent on future developments, which are still~~including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time, and include the duration, severity and scope of the outbreak and the actions taken to contain or treat the coronavirus outbreak. In particular, the spread of the coronavirus globally is adversely affecting global economies and financial markets which could materially and adversely impact our operations including, without limitation, the functioning of our laboratories, the availability of supplies including reagents, the progress and data collection of our pharma services, customer demand and travel and employee health and availability.
Wetime. Accordingly, we believe that the COVID-19 pandemic ~~will~~could continue to adversely impact our results of operations, cash flows and financial condition ~~for~~in the ~~second quarter of fiscal 2020 and possibly beyond. Our fiscal 2020 first quarter revenue was~~future.
As our business operations continue to be impacted by ~~lower than expected clinical service volume throughout March 2020, which~~the pandemic, we believe has resulted from the temporary reduction in non-essential testing procedures in connection with the COVID-19 pandemic. Our pharma services first quarter revenue increased throughout the first quarter and average daily accessions improved in March 2020 as compared to January and February 2020. However, as of the date of this Report, our overall business is still down approximately 30% from our run rate before the pandemic.
We continue to monitor the ~~rapidly evolving~~ situation and the guidance ~~from authorities, including~~that is being provided by relevant federal, state and local public health ~~authorities and~~authorities. We may take additional actions based onupon their recommendations. ~~In these dynamic circumstances, there~~However, it is possible that we may ~~be developments outside our control requiring us~~have to ~~adjust~~make further adjustments to our operating ~~plan.~~plans in reaction to developments that are beyond our control.
~~At this time,~~
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
While we do not anticipate any lab closures at this time beyond periodic, temporary work stoppages ~~from time to time~~ to clean and disinfect the ~~labs. Lab~~labs, this could change in the future based upon conditions caused by the pandemic. Further, while we have acquired additional inventories of lab supplies, including reagents, ~~have been secured to mitigate any potential~~it is possible that we could experience supply chain ~~issues~~shortages if the pandemic continues for a prolonged period and if one or more suppliers is unable to continue to provide us with supplies. For the foreseeable future, ~~and~~however, we ~~are~~do not ~~observing any shortages due to~~anticipate supply chain ~~issues. Our third party clinical services billing and collections company has taken steps to continue operations remotely.~~
~~We are monitoring the situation on a daily basis and have developed contingency plans to potentially mitigate the anticipated adverse financial impact~~shortages of the COVID-19 pandemic. These contingency plans include significant cost saving actions to offset any volume shortfall and additional action plans to react to further potential declines. While we are continuing to make progress on a regular basis in returning to volumes prior to the pandemic there is, however, no guarantee in the future we will recover the business which has been lost or inactive.
~~Restatement~~critical supplies.

We have ~~restated herein~~developed and will continue to update our unaudited consolidated financial statements as of March 31, 2020 for the three months ended March 31, 2020 and March 31, 2020. We have also restated impacted amounts within the accompanying footnotes to the consolidated financial statements which have been noted as such.
As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basiscontingency plans in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assetsmitigate pandemic-related, adverse financial impacts upon ~~launch of the test.~~our business.

On December 7, 2020, the Company’s management conferred with the Audit Committee of the Company’s Board of Directors and concluded that (1) a non-cash impairment charge for an intangible asset of approximately $12 million should have been recorded during the Company’s 2016 fiscal year; (2) the Company should have initiated amortization of such intangible asset in fiscal 2014 and therefore each of fiscal years 2014, 2015, 2016, 2017, 2018, and 2019 and the first two quarters of fiscal 2020 require adjustment to record amortization expense; (3) the consolidated financial statements contained in the Company’s Annual Reports on Form 10-K for the years ended December 31, 2014, 2015, 2016, 2017, 2018, and 2019, as well as the consolidated financial statements contained in the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020, should no longer be relied upon. As a result the Company is restating its consolidated financial statements for the three months ended March 31, 2020 and March 31, 2019 in this Form 10-Q/A.
The following tables present reconciliation from our prior periods as previously reported to the restated values for the consolidated balance sheets and the consolidated statement of operations. A description of misstatements is listed below:
a)
Amortization expense - We recorded amortization expense starting at the dates of acquisition for our Barrett’s and Thyroid intangible assets. The impact of the additional amortization charge was approximately $0.1 million in the quarters ended March 31, 2020 and March 31, 2019, respectively.
b)
~~Asset impairment - We recorded an impairment charge on our Barrett’s intangible asset of approximately $11.6 million in the fourth quarter of 2016.~~
c) ~~Adjustments - Adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years’ financial statements.~~
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED BALANCE SHEET~~
~~(in thousands, except share and per share data)~~
March 31, 2020
As
Previously
Reported Restatement
Amount Restatement
Reference As Restated
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 13,370 $ -             $ 13,370
Accounts receivable, net of allowance for doubtful accounts of $275 9,799 - 9,799
Other current assets 4,976 - 4,976
Total current assets 28,145 - 28,145
Property and equipment, net 6,610 6,610
Other intangible assets, net 32,470 (17,736 ) (a) (b) 14,734
Goodwill 8,433 - 8,433
Operating lease right of use assets 2,811 - 2,811
Other long-term assets 42 - 42
Total assets $ 78,511 $ (17,736 ) $ 60,775

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 4,456 $ - $ 4,456
Accrued salary and bonus 1,865 - 1,865
Other accrued expenses 8,639 - 8,639
Current liabilities from discontinued operations 766 - 766
Total current liabilities 15,726 - 15,726
Contingent consideration 2,264 - 2,264
Operating lease liabilities, net of current portion 1,384 - 1,384
Line of credit 1,200 - 1,200
Other long-term liabilities 4,563 - 4,563
Total liabilities 25,137 - 25,137

Commitments and contingencies (Note 8)

Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B shares issued and outstanding 46,536 - 46,536

Stockholders’ equity:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,055,454 and 4,043,673 shares issued and outstanding, respectively; 402 - 402
Additional paid-in capital 182,580 - 182,580
Accumulated deficit (174,423 ) (17,736 ) (a) (b) (c) (192,159 )
Treasury stock, at cost (11,781 shares) (1,721 ) - (1,721 )
Total stockholders’ equity 6,838 (17,736 ) (10,898 )
Total liabilities and stockholders’ equity $ 31,975 $ (17,736 ) $ 14,239

Total liabilities, preferred stock and stockholders’ equity $ 78,511 $ (17,736 ) $ 60,775
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS~~
~~(unaudited, in thousands, except for per share data)~~
Three Months Ended March 31, 2020 Three Months Ended March 31, 2019
As Previously Reported Restatement Amount Restatement Reference As Restated As Previously Reported Restatement Amount Restatement Reference As Restated

Revenue, net $ 9,200 $ (141 ) (c) $ 9,059 $ 6,010 $ - $ 6,010
Cost of revenue 6,113 - 6,113 2,622 - 2,622
Gross profit 3,087 (141 ) (c) 2,946 3,388 - 3,388
Operating expenses:
Sales and marketing 2,481 - 2,481 2,411 - 2,411
Research and development 809 - 809 528 - 528
General and administrative 4,887 6 (c) 4,893 2,912 (177 ) (c) 2,735
Acquisition related amortization expense 1,031 84 (a) 1,115 813 84 (a) 897
Total operating expenses 9,208 90 (a) (c) 9,298 6,664 (93 ) (a) (c) 6,571

Operating loss (6,121 ) (231 ) (a) (c) (6,352 ) (3,276 ) 93 (a) (c) (3,183 )
Interest accretion (109 ) - (109 ) (129 ) - (129 )
Other income (expense), net 47 - 47 48 - 48
Loss from continuing operations before tax (6,183 ) (231 ) (a) (c) (6,414 ) (3,357 ) 93 (a) (c) (3,264 )
Provision for income taxes 15 - 15 5 - 5
Loss from continuing operations, net of tax (6,198 ) (231 ) (a) (c) (6,429 ) (3,362 ) 93 (a) (c) (3,269 )

Loss from discontinued operations, net of tax (65 ) - (65 ) (57 ) - (57 )

Net loss (6,263 ) (231 ) (a) (c) (6,494 ) (3,419 ) 93 (a) (c) (3,326 )

Less adjustment for preferred stock deemed dividend (3,033 ) - (3,033 ) - - -

Net loss attributable to common stockholders (9,296 ) (231 ) (9,527 ) (3,419 ) 93 (3,326 )

Basic and diluted loss per share of common stock:
From continuing operations $ (2.31 ) $ (0.06 ) $ (2.37 ) $ (0.96 ) $ 0.03 $ (0.93 )
From discontinued operations (0.01 ) - (0.01 ) (0.01 ) - (0.01 )
Net loss per basic and diluted share of common stock $ (2.32 ) $ (0.06 ) $ (2.38 ) $ (0.97 ) $ 0.03 $ (0.94 )
Weighted average number of common shares and common share equivalents outstanding:
Basic 4,004 4,004 4,004 3,515 3,515 3,515
Diluted 4,004 4,004 4,004 3,515 3,515 3,515
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY~~
~~(unaudited, in thousands)~~
As Previously Reported As Restated
For The Three Months Ended For The Three Months Ended
March 31, 2020 Restatement Restatement March 31, 2020
Shares Amount Amount Reference Shares Amount
Common stock:
Balance at January 1 3,932 $ 393 $ -        3,932 $ 393
Common stock issued 37 1 - 37 1
Restricted stock issued 6 - - 6 -
Common stock issued through market sales 80 8 - 80 8
Common stock issued through offerings - - - - -
Balance at March 31 4,055 402 - 4,055 402
Treasury stock:
Balance at January 1 12 (1,721 ) - 12 (1,721 )
Treasury stock purchased - - - - -
Balance at March 31 12 (1,721 ) - 12 (1,721 )
Additional paid-in capital:
Balance at January 1 182,514 - 182,514
Common stock issued through offerings, net of expenses - - -
Extinguishment of Series A Shares (828 ) - (828 )
Beneficial Conversion Feature in connection with Series B Issuance 2,205 - 2,205
Amortization of Beneficial Conversion Feature (2,205 ) - (2,205 )
Common stock issued through market sales 476 - 476
Stock-based compensation expense 418 - 418
Balance at March 31 182,580 - 182,580
Accumulated deficit:
Balance at January 1 (168,160 ) (17,505 )
(a)(b)(c)
(185,665 )
Net loss (6,263 ) (231 )
(a)(c)
(6,494 )
Adoption of ASC 842 - - -
Balance at March 31 (174,423 ) (17,736 ) (192,159 )

Total stockholders’ equity $ 6,838 $ (17,736 ) $ (10,898 )
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY~~
~~(unaudited, in thousands)~~
As Previously Reported As Restated
For The Three Months Ended For The Three Months Ended
March 31, 2019 Restatement Restatement March 31, 2019
Shares Amount Amount Reference Shares Amount
Common stock:
Balance at January 1 2,877 $ 287 $ -         2,877 $ 287
Common stock issued 9 1 - 9 1
Restricted stock issued - - - - -
Common stock issued through market sales - - - - -
Common stock issued through offerings 933 94 - 933 94
Balance at March 31 3,819 382 - 3,819 382
Treasury stock:
Balance at January 1 7 (1,680 ) - 7 (1,680 )
Treasury stock purchased 3 (32 ) - 3 (32 )
Balance at March 31 10 (1,712 ) - 10 (1,712 )
Additional paid-in capital:
Balance at January 1 175,820 - 175,820
Common stock issued through offerings, net of expenses 5,868 - 5,868
Extinguishment of Series A Shares - - -
Beneficial Conversion Feature in connection with Series B Issuance - - -
Amortization of Beneficial Conversion Feature - - -
Common stock issued through market sales - - -
Stock-based compensation expense 266 - 266
Balance at March 31 181,954 - 181,954
Accumulated deficit:
Balance at January 1 (141,489 ) (17,492 ) (a)(b)(c)
(158,981 )
Net loss (3,419 ) 93 (a)(c)
(3,326 )
Adoption of ASC 842 55 - 55
Balance at March 31 (144,853 ) (17,399 ) (162,252 )

Total stockholders’ equity $ 35,771 $ (17,399 ) $ 18,372
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~
~~(unaudited, in thousands)~~
For The Three Months Ended March 31,
2020 2020
As Previously
Reported Restatement
Amount Restatement
Reference As Restated

Cash Flows From Operating Activities
Net loss $ (6,263 ) $ (231 ) (a)(c) $ (6,494 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 1,235 84 (a) 1,319
Interest accretion 109 - 109
Mark to market on warrants (26 ) - (26 )
Stock-based compensation 418 - 418
Bad debt expense 250 - 250
Other gains and expenses, net - - -
Other changes in operating assets and liabilities:
Decrease (increase) in accounts receivable 148 141 (c) 289
(Increase) decrease in other current assets (1,125 ) - (1,125 )
(Decrease) increase in accounts payable (356 ) 103 (c) (253 )
(Decrease) increase in accrued salaries and bonus �� (476 ) - (476 )
(Decrease) increase in accrued liabilities (1,052 ) (97 ) (c) (1,149 )
Increase in long-term liabilities 16 - 16
Net cash used in operating activities (7,122 ) - (7,122 )

Cash Flows From Investing Activity
Purchase of property and equipment - - -
Sale of property and equipment - - -
Net cash provided by investing activity - - -

Cash Flows From Financing Activities
Issuance of common stock, net of expenses 434 - 434
Payments on Line of Credit (1,800 ) - (1,800 )
Issuance of Series B preferred stock, net of expenses 19,537 - 19,537
Net cash provided by financing activities 18,171 - 18,171

Net increase in cash and cash equivalents 11,049 - 11,049
Cash and cash equivalents – beginning 2,321 - 2,321
Cash and cash equivalents – ending $ 13,370 $ - $ 13,370
~~INTERPACE BIOSCIENCES, INC.~~
~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~
~~(unaudited, in thousands)~~
For The Three Months Ended March 31,
2019 2019
As Previously
Reported Restatement
Amount Restatement
Reference As Restated

Cash Flows From Operating Activities
Net loss $ (3,419 ) $ 93 (a)(c) $ (3,326 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 873 84 (a) 957
Interest accretion 129 - 129
Mark to market on warrants (3 ) - (3 )
Stock-based compensation 538 - 538
Bad debt expense - - -
Other gains and expenses, net 18 - 18
Other changes in operating assets and liabilities:
Decrease (increase) in accounts receivable (1,738 ) - (1,738 )
(Increase) decrease in other current assets 11 - 11
(Decrease) increase in accounts payable 93 - �� 93
(Decrease) increase in accrued salaries and bonus 325 (120 ) (c) 205
(Decrease) increase in accrued liabilities 156 (57 ) (c) 99
Increase in long-term liabilities 57 - 57
Net cash used in operating activities (2,960 ) - (2,960 )

Cash Flows From Investing Activity
Purchase of property and equipment (12 ) - (12 )
Sale of property and equipment 13 - 13
Net cash provided by investing activity 1 - 1

Cash Flows From Financing Activities
Issuance of common stock, net of expenses 6,015 - 6,015
Net cash provided by financing activities 6,015 - 6,015

Net increase in cash and cash equivalents 3,056 - 3,056
Cash and cash equivalents – beginning
6,068
-
6,068

Cash and cash equivalents – ending $
9,124
$ - $
9,124

2. BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of ~~Interpace Biosciences, Inc. (the “Company” or “Interpace”),~~the Company and its wholly-owned subsidiaries ~~Interpace~~(Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, Interpace Pharma Solutions, Inc. and Interpace Diagnostics, ~~LLC,~~LLC), and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the ~~SEC~~Securities & Exchange Commission (“SEC”) on April 22, 2020 and as amended on May 29, 2020 and ~~the date hereof~~January 19, 2021 (the “Form 10-K”).

The condensed Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, ~~or Group DCA;~~ InServe Support Solutions; and TVG, Inc. and its Commercial Services ~~(“CSO”)~~ business unit which was sold on December 22, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the reverse stock split (1 for 10) that occurred in January 2020.

3. ~~LIQUIDITY~~GOING CONCERN

The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.
As of ~~March 31,~~September 30, 2020, the Company had cash and cash equivalents of ~~$13.4~~$5.3 million, net accounts receivable of ~~$9.8~~$8.5 million, total current assets of ~~$28.1~~$17.6 million and total current liabilities of ~~$15.7~~$15.6 million. For the ~~three-months~~nine month period ended ~~March 31,~~September 30, 2020, the Company had a net loss of ~~$6.5~~$18.3 million and cash used in operating activities was ~~$7.1~~$12.4 million.
~~We do not expect to generate positive~~ As of January 15, 2021 we had approximately $6.1 million of cash ~~flows from operations for~~on hand, net of restricted cash. During the ~~year ending December 31, 2020. We intend to meet our ongoing capital needs by using our available cash, proceeds under~~second and third quarters of fiscal 2020 the Securities Purchase and Exchange Agreement, additional borrowings under the Line of Credit as well as by increasing our line of credit limit as a result of the additional accounts receivable acquired in July 2019 as part of our acquisition of the Biopharma business of Cancer Genetics, Inc. or CGI, now our pharma services (which requires a modificationCompany experienced slower collections due to the ~~bank agreement~~pandemic and ~~approval by~~in September 2020, we repaid approximately $3.4 million to Silicon Valley Bank (“SVB”) under our former secured revolving line of credit facility (the “Revolver”), ~~revenue growth~~which was part of our Loan and ~~margin improvement, collecting~~Security Agreement with SVB dated November 13, 2018, as amended March 18, 2019 (as so amended, the “SVB Loan Agreement”). On January 5, 2021, the Company terminated the SVB Loan Agreement. See Note 14, Revolver and Note 19, Subsequent Events.
The Revolver had a limit of up to $4.0 million, available for working capital purposes, and an original maturity date of November 13, 2021. Prior to the termination, the borrowing limit of the Revolver was (a) the lower of: (i) $4.0 million and (ii) 80% of the Company’s eligible accounts receivable ~~containing costs~~(as adjusted by SVB), reduced by (b) (i) any outstanding advances under the Revolver, of which there are none as ~~well as exploring other financing options. Management believes that~~of September 30, 2020; (ii) the Landlord Letter of Credit, in the maximum amount of $1 million; and (iii) any outstanding term loans, of which there was none due to repayment in 2019.
As of July 31, 2020, the Company ~~has sufficient~~was in violation of a financial covenant under the SVB Loan Agreement. Additionally, due to the untimely filing of our second quarter Form 10-Q with the SEC, the Company was in default under the SVB Loan Agreement. During September 2020, the Company paid down the outstanding Revolver balance of $3.4 million in full and transferred $0.35 million into a restricted cash money market account with SVB to serve as collateral for the Company’s letters of credit supporting its leased facilities. Prior to September 2020, the collateral for the letters of credit was accounted for as a reduction in the availability under the Revolver. As of September 30, 2020 there was no balance outstanding on ~~hand~~the Revolver. SVB agreed to forebear from exercising its rights and ~~sufficient access~~remedies with respect to ~~cash to sustain operations through at least June 30, 2021.~~the default on October 19, 2020.

During October 2020, the Company further amended the SVB Loan Agreement (the “Second Amendment”), adding the Company’s subsidiary, Interpace Pharma Solutions, Inc. (“IPS”) as a borrower thereunder and granting SVB a continuing lien upon and security interest in all of the assets of IPS (See Note 19, Subsequent Events).
Under the terms of the SVB Loan Agreement, the Company had covenants to maintain at all times an Adjusted Quick Ratio of at least 1.15 to 1.0. SVB waived the Company’s failure to comply with such requirement for the months ended July 31, 2020 and August 31, 2020 and agreed to forebear financial covenant testing while the Revolver was not drawn. With respect to any principal amount that was outstanding under the Revolver, the Second Amendment increased the floating per annum rate of interest to the greater of (A) one percent (1.0%) above the Prime Rate (as defined in the SVB Loan Agreement) and (B) four and one-quarter of one percent (4.25%). Prior to the Second Amendment, such interest accrued at a rate equal to one-half of one percent (0.50%) above the Prime Rate.
The Company had been in compliance with the terms of the SVB Loan Agreement through the date of termination of the SVB Loan Agreement.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
In September 2019, we entered into the Equity Distribution Agreement (the ~~“Agreement”~~“Equity Distribution Agreement”) with Oppenheimer & Co. Inc., as sales agent (the “Agent”), pursuant to which we may, from time to time, issue and sell shares of our common stock inwith an aggregate offering price of up to ~~$4.8~~$3.7 million through the ~~Agent. See Note 16,~~ ~~Equity~~~~, for more details. As of March 31,~~Agent (the “ATM arrangement”). During the nine months ended September 30, 2020, approximately 178,000 shares of common stock were sold for net proceeds of approximately $0.7 million. As a result of the preferred shares transaction mentioned below, additional shares may no longer be sold under the ATM arrangement without a majority approval by the holders of the preferred shares. ~~See Note 16,~~ In addition, if our common stock is delisted by The Nasdaq Stock Market LLC (“Nasdaq”) due to our failure to meet minimum stockholders’ equity requirements, we may no longer be eligible to sell under the Equity~~, for more detail.~~ Distribution Agreement.

In January 2020, we sold 20,000 Series B preferred shares to investors, led by 1315 Capital II, L.P. (“1315 Capital”), for net proceeds of approximately ~~$19.5~~$19.2 million. See Note 16, Equity, for more detail.

The Company maintains an up to a $4.0 million secured Line of Credit facility including a 3-year term loan for $850,000 with SVB. The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company’s eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months. Term loan outstanding amounts incur interest at a rate per annum equal to the greater of the Wall Street Journal Prime Rate (the “Prime Rate”) and 5.00%. Revolving Line outstanding amounts incur interest at a rate per annum equal to the Prime Rate plus 0.5%. As of March 31, 2020, $1.2 million was outstanding and $2.2 million was remaining on the Line of Credit.
See Note 1, Overview, regarding the potential adverse impact of the COVID-19 pandemic on our results of operations, cash flows and financial condition for the ~~second~~third quarter of fiscal 2020 and possibly beyond.

During April 2020, the Company applied for various federal stimulus grants and advances made available under Title 1 of the Coronavirus Aid, Relief, and Economic Security (CARES) ~~Act.~~Act (the “CARES Act”). As of ~~May 1,~~September 30, 2020, we received $2.1 million in advances under the Centers for Medicare & Medicaid Services ~~(CMS)~~(“CMS”) accelerated and advance payment program, as well as a $0.65 million grant from the Department of Health and Human Services ~~(HSS)~~(“HHS”). The CMS advance will be offset against future Medicare billings of the Company, and we applied the ~~HSS~~HHS grant ~~is subject~~in its entirety towards qualified second quarter expenses. These expenses related to ~~certain conditions regarding its use,~~lab equipment and supplies purchased to prevent, prepare for, and respond to coronavirus, including ~~developing~~development of coronavirus and serology ~~tests. These grants and advances require certain certifications~~tests, as well as expenses that would have been covered by revenue lost to coronavirus during the ~~Company and impose specific limitations on~~second quarter. CMS will begin to utilize the ~~use~~$2.1 million advanced payment against cash payments beginning in the second quarter of the proceeds. Based on these restrictions and limitations, the Company is treating the $0.65 million HSS grant as restricted cash until we have clarity on how the funds can be utilized by the Company based on the specific requirements of the HSS.2021.

During April and early May 2020, the Company made payments totaling $888,000 to ~~CGI~~Cancer Genetics Inc. (“CGI”) for funds withheld from the Excess Consideration Note to satisfy certain adjustments and indemnification obligations under the Secured Creditor Asset Purchase ~~Agreement.~~ Agreement dated July 15, 2019 in connection with the acquisition of the biopharma business of CGI.
On January 7, 2021, the Company entered into a $3 million loan through a secured promissory note with Ampersand 2018 Limited Partnership (“Ampersand”) and a $2 million loan through a secured promissory note with 1315 Capital, its Series B shareholders. Both loans are secured by substantially all of the Company’s assets. See Note 19, Subsequent Events.
The ~~funds used to satisfy this obligation were not included in~~Company’s cash and cash equivalents ~~as of~~balance is decreasing and we will not generate positive cash flows from operations for the year ending December 31, ~~2019~~2020. We intend to meet our ongoing capital needs by using our available cash, including the loans from Ampersand and ~~March 31, 2020. These funds~~1315 Capital, as well as revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the ~~related liability were included in Other Assets~~potential use of other financing options.
The Company has and ~~Other Current Liabilities, respectively,~~may continue to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as ~~of those period ends, and the settlement of the liability had no net impact on the Company’s operating cash flow or liquidity.~~
~~As of June 17, 2020 we have approximately $16.2 million of cash on hand. Also as of June 17, 2020,~~ the Company ~~has no further availability on its credit facility, but~~ is successful in ~~the process~~securing additional funding. The Company is exploring various dilutive and non-dilutive sources of ~~completing an agreement with SVB to expand the credit facility. No assurance can be given that such an expansion agreement will be entered into.~~
~~Upon the filing of this Form 10Q/A, the Company’s stockholders’~~funding, including equity ~~as of March 31, 2020 was below the minimum required by Nasdaq.~~and debt financings, strategic alliances, business development and other sources. In the event the ~~Company~~Company’s Common Stock is ~~unable to maintain its~~delisted from Nasdaq ~~listing for its common stock~~ due to aits failure to meet minimum ~~stockholder~~stockholders’ equity requirements, ~~due to the classification of its preferred stock as temporary equity and as a result of the amortization and impairment of certain intangible assets set forth herein,~~ the Company’s ability to raise additional capital may be materially adversely impacted. ~~Therefore, there~~In addition, the Company’s inability to use Form S-3 after it files its Form 10-K for the fiscal year ended December 31, 2020 may have an adverse impact on our ability to raise additional capital. The future success of the Company is ~~no guarantee that~~dependent upon its ability to obtain additional ~~capital~~funding. There can be ~~raised~~no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to ~~fund our future operations.~~the Company, or at all. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated cash requirements through the end of the second quarter. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.

Revenue Recognition

Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which ~~would affect~~affects net revenue in the period such variances become known.

For our pharma services, ~~performance~~project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. ~~Project level activities, including study setup and project management, are satisfied over the life of the contract.~~ Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

Deferred Revenue

For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.

18
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

Financing and Payment

For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical ~~or diagnostics business~~services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers.

Costs to Obtain or Fulfill a Customer Contract

Sales commissions are expensed ~~when incurred because~~in the ~~amortization~~ period ~~would~~in which they have been ~~one year or less.~~earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.

Accounts Receivable

The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by ~~third party~~third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.

Leases

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
Other Current Assets

Other current assets consisted of the following as of ~~March 31,~~September 30, 2020 and December 31, 2019:

September 30, 2020 December 31, 2019
(unaudited)
Lab supply inventory 2,423 1,825
Prepaid expenses 489 971
Funds in escrow - 888
Letter of credit 350 -
Due from CGI 525 92
Other 74 75
Total other current assets $ 3,861 $ 3,851
March 31, 2020 December 31, 2019
(unaudited)
Lab supply inventory 1,885 1,825
Prepaid expenses 826 971
Funds in escrow 888 888
Due from CGI 1,297 92
Other 80 75
Total other current assets $ 4,976 $ 3,851

Long-Lived Assets, including Finite-Lived Intangible Assets

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in ~~acquisition related~~acquisition-related amortization expense in the condensed consolidated statements of operations.

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

Basic and Diluted Net Loss per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share, ~~(the “Common Stock”),~~ used in the calculation of basic and diluted loss per share for the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2020 and 2019 is as follows:

Three Months Ended Three Months Ended Nine Months Ended
March 31, September 30, September 30,
2020 2019 2020 2019 2020 2019
(unaudited) (unaudited) (unaudited)
Basic weighted average number of common shares 4,004 3,515 4,038 3,820 4,025 3,717
Potential dilutive effect of stock-based awards - - - - - -
Diluted weighted average number of common shares 4,004 3,515 4,038 3,820 4,025 3,717
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares for the ~~three months~~three- and nine-months ended ~~March 31,~~September 30, 2020, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

Three Months Ended Three Months Ended Nine Months Ended
March 31, September 30, September 30,
2020 2019 2020 2019 2020 2019
(unaudited) (unaudited) (unaudited)
Options 578 394 878 394 878 394
Stock-settled stock appreciation rights (SARs) - 3 - 2 - 2
Restricted stock 6 -
Restricted stock units (RSUs) 36 61 28 54 28 54
Warrants 1,420 1,420 1,405 1,420 1,405 1,420
2,040 1,878 2,311 1,870 2,311 1,870

5. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill is attributable to the acquisition of our pharma services in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at ~~March 31,~~September 30, 2020 was $8.4 million. The net carrying value of the identifiable intangible assets from all acquisitions as of ~~March 31,~~September 30, 2020 and December 31, 2019 are as follows:

As Restated As Restated
As of March 31, 2020 As of December 31, 2019
As of September
30, 2020

As of December
31, 2019

Life Carrying Carrying Life Carrying Carrying
(Years) Amount Amount (Years) Amount Amount

Asuragen acquisition:
Thyroid 9 $ 8,519 $ 8,519 9 $ 8,519 $ 8,519
RedPath acquisition:
Pancreas test 7 16,141 16,141 7 16,141 16,141
Barrett’s test 9 6,719 6,719 9 6,719 6,719
BioPharma acquisition:
Trademarks 10 1,600 1,600 10 1,600 1,600
Customer relationships 8 5,700 5,700 8 5,700 5,700

CLIA Lab 2.3 $ 609 $ 609 2.3 $ 609 $ 609

Total $ 39,288 $ 39,288 $ 39,288 $ 39,288

Accumulated Amortization $ (24,554 ) $ (23,439 ) $ (26,784 ) $ (23,439 )

Net Carrying Value $ 14,734 $ 15,849 $ 12,504 $ 15,849
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
Amortization expense was approximately $1.1 million for both the three-month periods ended September 30, 2020 and 2019, respectively, and approximately $3.3 million and $2.9 million for the nine-month periods ended September 30, 2020 and 2019, respectively. Estimated amortization expense for the next five years is as follows:
2020 2021 2022 2023 2024

$ 4,871 $ 4,078 $ 2,156 $ 1,745 $ 873

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2019 to ~~March 31,~~September 30, 2020:

Carrying
Amount
Balance as of December 31, 2019 $ 8,433
Adjustments -
Balance as of March 31, 2020 $ 8,433
Amortization expense was approximately $1.1 million and $0.9 million for the three-month periods ended March 31, 2020 and 2019, respectively. Estimated amortization expense for the next five years is as follows:
As Restated
2020 2021 2022 2023 2024

$ 4,871 $ 4,078 $ 2,156 $ 1,745 $ 873
Carrying
Amount
Balance as of December 31, 2019 $ 8,433
Adjustments -
Balance as of September 30, 2020 $ 8,433

6. FAIR VALUE MEASUREMENTS

Cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

As of September 30, 2020 Fair Value Measurements
As of March 31, 2020 Fair Value Measurements Carrying Fair As of September 30, 2020
Carrying Fair As of March 31, 2020 Amount Value Level 1 Level 2 Level 3
Amount Value Level 1 Level 2 Level 3 (unaudited)
Liabilities: (unaudited)
Contingent consideration:
Asuragen ⁽¹⁾ $ 2,866 $ 2,866 $ - $ - $ 2,866 $ 2,806 $ 2,806 $ - $ - $ 2,806
Other long-term liabilities:
Warrant liability ⁽²⁾ 55 55 - - 55 20 20 - - 20
$ 2,921 $ 2,921 $ - $ - $ 2,921 $ 2,826 $ 2,826 $ - $ - $ 2,826

As of December 31, 2019 Fair Value Measurements
Carrying Fair As of December 31, 2019
Amount Value Level 1 Level 2 Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾ $ 2,893 $ 2,893 $ - $ - $ 2,893
Other long-term liabilities:
Warrant liability ⁽²⁾ 82 82 - - 82
$ 2,975 $ 2,975 $ - $ - $ 2,975

⁽¹⁾⁽²⁾See Note 9, Accrued Expenses and Long-Term Liabilities

In connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to ~~March 31,~~September 30, 2020 is as follows:
Cancellation Adjustment
of Obligation/ to Fair Value/

December 31,
2019
Payments Accretion
Conversions
Exercises

Mark to
Market

March 31,
2020
(unaudited)
Asuragen $ 2,893 $ (136 ) $ 109 $      - $     - $ 2,866

Underwriters Warrants 82 - - - (27 ) 55
$ 2,975 $ (136 ) $ 109 $ - $ (27 ) $ 2,921

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
Cancellation of Obligation/ Adjustment to Fair Value/
December 31, 2019 Payments Accretion Conversions Exercises Mark to Market September 30, 2020
(unaudited)
Asuragen $ 2,893 $ (501 ) $ 414 $        - $ - $ 2,806

Underwriters Warrants 82 - - - (62 ) 20
$ 2,975 $ (501 ) $ 414 $ - $ (62 ) $ 2,826
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
7. LEASES

Finance lease assets are included in fixed assets, net of accumulated depreciation.

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

Classification on the Balance Sheet March 31, 2020 Classification on the Balance Sheet September 30, 2020
(unaudited) (unaudited)
Assets
Financing lease assets Property and equipment, net $ 475 Property and equipment, net $ 470
Operating lease assets Operating lease right of use assets 2,811 Operating lease right of use assets 4,758
Total lease assets $ 3,286 $ 5,228

Liabilities
Current
Financing lease liabilities Other accrued expenses $ 160 Other accrued expenses $ 134
Operating lease liabilities Other accrued expenses 1,251 Other accrued expenses 1,110
Total current lease liabilities $ 1,411 $ 1,244
Noncurrent
Financing lease liabilities Other long-term liabilities 85 Other long-term liabilities 33
Operating lease liabilities Operating lease liabilities, net of current portion 1,384 Operating lease liabilities, net of current portion 3,746
Total long-term lease liabilities 1,469 3,779
Total lease liabilities $ 2,880 $ 5,023

The weighted average remaining lease term for the Company’s operating leases was ~~2.6~~7.1 years as of ~~March 31,~~September 30, 2020 and the weighted average discount rate for those leases was 6.0%. The Company’s operating lease expenses are recorded within ~~cost~~“Cost of ~~revenue~~revenue” and ~~general~~“General and administrative expenses.” With respect to the Rutherford lease, in March 2020 the Company delivered a notice of early termination which would terminate the lease in March 2021.As a result of entering into an early termination of the Rutherford lease the Company’s operating lease assets and liabilities decreased by approximately $0.5 million.
In June 2020, the Company entered into an amendment of its North Carolina lease extending it for an additional ten years, commencing on June 1, 2020 and continuing until May 31, 2030. The minimum rent per rentable square foot pursuant to the amendment is $14.10 from June 1, 2020 to May 31, 2021, with annual increases of 3%. Pursuant to the amendment, the Company has two options to extend the term for a period of five years each. Also pursuant to the amendment, the Company has the irrevocable right to terminate the lease on November 30, 2025, as well as on November 30, 2027. As a result of entering into an amendment of the North Carolina lease the Company’s operating lease assets and liabilities increased by approximately $2.8 million.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of ~~March 31,~~September 30, 2020:

Operating Leases Financing Leases Operating Leases Financing Leases
2020 1,189 170 365 49
2021 878 120 1,235 120
2022 660 13 1,028 13
2023 250 - 629 -
2024-2030 2,717
Total minimum lease payments 2,977 303 5,974 182
Less: amount of lease payments representing effects of discounting 342 58 1,118 13
Present value of future minimum lease payments 2,635 245 4,856 169
Less: current obligations under leases 1,251 160 1,110 134
Long-term lease obligations $ 1,384 $ 85 $ 3,746 $ 35

As of ~~March 31,~~September 30, 2020, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows:

Less than 1 to 3 3 to 5 After
Total 1 Year Years Years 5 Years
Operating lease obligations $ 2,977 $ 1,189 $ 1,538 $ 250 $ -
Less than 1 to 3 3 to 5 After
Total 1 Year Years Years 5 Years
Operating lease obligations $ 5,974 $ 365 $ 2,263 $ 1,020 $ 2,326
Total $ 5,974 $ 365 $ 2,263 $ 1,020 $ 2,326

8. COMMITMENTS AND CONTINGENCIES
Litigation
From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

Due to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products that the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business ~~activities~~activities. There is also the risk of employment related litigation and ~~recent increases~~other litigation in ~~litigation related to healthcare products.~~the ordinary course of business.

The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of ~~March 31,~~September 30, 2020 and December 31, 2019:

As Restated As Restated
March 31, 2020 December 31, 2019 September 30, 2020 December 31, 2019
(unaudited) (unaudited)
Accrued royalties $ 2,101 $ 1,934 $ 2,487 $ 1,934
Contingent consideration 602 502 676 502
Upfront Medicare payment 2,066 -
Operating lease liability 1,251 1,321 1,110 1,321
Financing lease liability 160 184 134 184
Deferred revenue 354 457 69 457
Payable to CGI 888 888 - 888
Accrued sales and marketing - diagnostics 167 197 111 197
Accrued lab costs - diagnostics 104 163 150 163
Accrued professional fees 1,064 1,399 1,090 1,399
Taxes payable 327 403 301 403
Unclaimed property 565 565 565 565
All others 1,056 1,463 1,372 1,463
Total other accrued expenses $ 8,639 $ 9,476 $ 10,131 $ 9,476

Long-term liabilities consisted of the following as of ~~March 31,~~September 30, 2020 and December 31, 2019:

March 31, 2020 December 31, 2019
(unaudited)
Warrant liability $ 55 $ 82
Uncertain tax positions 4,146 4,081
Deferred revenue 258 269
Other 104 141
Total other long-term liabilities $ 4,563 $ 4,573
September 30, 2020 December 31, 2019
(unaudited)
Warrant liability $ 20 $ 82
Uncertain tax positions 4,293 4,081
Deferred revenue 140 269
Other 33 141
Total other long-term liabilities $ 4,486 $ 4,573

10. STOCK-BASED COMPENSATION
Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally ~~vested~~vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. ~~Restricted shares and RSUs granted~~In the second quarter of 2020, the Company issued performance-based options, which requires the Company to ~~Board members generally have~~assess the likelihood of achieving certain performance milestones on a ~~three-year graded vesting~~quarterly basis; approximately $0.3 million in stock compensation expense is expected to be incurred over the amortization period ~~and are subject to accelerated vesting and forfeiture under certain circumstances.~~for these options.

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the ~~three~~nine month periods ended ~~March 31,~~September 30, 2020 and 2019.

March 31, 2020 March 31, 2019 September 30, 2020 September 30, 2019
(unaudited) (unaudited)
Risk-free interest rate 1.51 % 2.51 % 0.79 % 2.51 %
Expected life 6.0 years 6.0 years
Expected term 6.59 years 6.0 years
Expected volatility 128.87 % 127.81 % 122.24 % 127.81 %
Dividend yield - - - -
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

The Company recognized approximately ~~$0.4~~$0.6 million and ~~$0.5~~$0.3 million of stock-based compensation expense during the three-month periods ended ~~March 31,~~September 30, 2020 and 2019, respectively, and approximately $1.4 million and $1.2 million for the nine-month periods ended September 30, 2020 and 2019, respectively.
11. INCOME TAXES

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on loss from continuing operations and the effective tax rate for the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2020 and 2019:

Three Months Ended Three Months Ended Nine Months Ended
March 31, September 30, September 30,
2020 2019 2020 2019 2020 2019
(unaudited) (unaudited) (unaudited)

Provision for income tax $ 15 $ 5 $ 14 $ 9 $ 43 $ 19
Effective income tax rate (0.2 %) (0.1 %) 0.2 % 0.1 % 0.2 % 0.1 %

Income tax expense for both the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2020 and 2019 was primarily due to minimum state and local taxes.

The ~~Coronavirus Aid, Relief, and Economic Security~~CARES Act ~~(the “CARES Act”)~~ was enacted in March 2020. The CARES Act includes several U.S. income tax provisions related to, among other things, net operating loss carrybacks, alternative minimum tax credits, modifications to the net interest deduction limitations, and technical amendments regarding the income tax depreciation of qualified improvement property placed in service after December 31, 2017. The CARES Act is not expected to have a material impact on the Company’s financial results.

12. SEGMENT INFORMATION

We operate under one segment which is the business of developing and selling ~~diagnostic~~ clinical and pharma services.

13. DISCONTINUED OPERATIONS

The components of liabilities classified as discontinued operations ~~relate to Commercial Services and~~ consist of the following as of ~~March 31,~~September 30, 2020 and December 31, 2019:

March 31, 2020 December 31, 2019 September 30, 2020 December 31, 2019
(unaudited) (unaudited)

Accrued liabilities 766 766 766 766
Current liabilities from discontinued operations 766 766 766 766
Total liabilities $ 766 $ 766 $ 766 $ 766
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2020 and 2019.
Three Months Ended Three Months Ended
September 30, September 30,
2020 2019 2020 2019
Income from discontinued operations, before tax $ - $ - $ - $ 122
Income tax expense 65 58 194 173
Loss from discontinued operations, net of tax $ (65 ) $ (58 ) $ (194 ) $ (51 )

14. ~~LINE OF CREDIT~~REVOLVER

On November 13, 2018, the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into athe SVB Loan ~~and Security~~ Agreement, ~~(the “SVB Loan Agreement”) with SVB,~~ which ~~provides~~provided for up to $4.0 million of debt financing ~~consisted~~consisting of a term loan of up to $850,000 and ~~a revolving line of credit~~the Revolver based on its outstanding accounts receivable ~~(the “Revolving Line”)~~ of up to $3.75 million. The ability to use the term loan portion of the SVB Loan Agreement expired in ~~2019.~~2019 and the Company terminated the SVB Loan Agreement on January 5, 2021. See Note 19, Subsequent Events.

~~The amount that may be borrowed under~~As a result of the ~~Revolving Line is~~Second Amendment, the borrowing limit of the Revolver prior to termination on January 5, 2021 was (a) the lower ofof: (i) ~~$3.75~~$4.0 million orand (ii) 80% of the Company’s eligible accounts receivable (as adjusted by SVB)~~. Revolving Line~~, reduced by (b) (i) any outstanding ~~amounts incur interest at a rate per annum equal~~advances under the Revolver, of which there were none as of September 30, 2020 and through the date of termination; (ii) the Landlord Letter of Credit, in the maximum amount of $1 million; and (iii) any outstanding term loans, of which there were none due to ~~the Wall Street Journal Prime Rate plus 0.5%.~~repayment in 2019. The ~~Company is also required to pay~~Revolver had an ~~unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The Revolving Line has a~~original maturity date three years from the effective date, or November 13, 2021.

As of ~~March~~July 31, 2020, the Company ~~had drawn $1.2 million of the available funds with the Revolving Line and had $2.55 million of remaining availability. As of December 31, 2019, we were~~was in violation of a financial covenant under its SVB Loan Agreement. Additionally, due to the untimely filing of our second quarter Form 10-Q with the SEC, the Company was in default under the SVB Loan Agreement. During September 2020, the Company paid down the outstanding Revolver balance of $3.4 million in full and transferred $0.35 million into a restricted cash money market account with SVB to serve as collateral for ~~which we received~~the Company’s letters of credit supporting its leased facilities. Prior to September 2020, the collateral for the letters of credit was accounted for as a ~~waiver~~reduction in the availability under the Revolver. As of September 30, 2020 there was no balance outstanding on the Revolver. SVB agreed to forebear from ~~SVB~~exercising its rights and remedies with respect to the default on ~~March~~October 19, 2020.
During October 2020, the Company entered into the Second Amendment with SVB, adding the Company’s subsidiary, IPS as a borrower thereunder and granting SVB a continuing lien upon and security interest in all of the assets of IPS (See Note 19, Subsequent Events).
Under the terms of the SVB Loan Agreement, the Company was required to maintain at all times an Adjusted Quick Ratio of at least 1.15 to 1.0. SVB waived the Company’s failure to comply with such requirement for the months ended July 31, 2020 and August 31, 2020 and agreed to forebear financial covenant testing while the Revolver was not drawn. With respect to any principal amount that was outstanding under the Revolver, the Second Amendment increased the floating per annum rate of interest to the greater of (A) one percent (1.0%) above the Prime Rate (as defined in the SVB Loan Agreement) and (B) four and one-quarter of one percent (4.25%). Prior to the Second Amendment, such interest accrued at a rate equal to one-half of one percent (0.50%) above the Prime Rate.
The Company ~~currently is~~had been in compliance with ~~all covenants.~~
Asthe terms of ~~June 17, 2020,~~ the ~~Company has maximized its borrowing under its line~~SVB Loan Agreement through the date of ~~credit facility and therefore has no further availability on its credit facility; however, we are in~~termination of the process of seeking to expand availability under the credit facility on terms similar to existing terms, but there can be no assurance that such credit line extension will be granted or that it will be granted on commercially reasonable and acceptable terms
SVB Loan Agreement.

15. SUPPLEMENTAL CASH FLOW INFORMATION

The following table represents cash flows used in the Company’s discontinued operations for the nine months ended September 30, 2020 and 2019:
Nine Months Ended
September 30,
2020 2019
(unaudited)
Net cash used in operating activities of discontinued operations $ - $ (30 )
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
Supplemental Disclosures of Non Cash Activities
(in thousands)

Nine Months Ended
September 30,
2020 2019
(unaudited)
Operating
Adoption of ASC 842 - right of use asset $ - $ 2,449
Adoption of ASC 842 - operating lease liability $ - $ 2,536
Prepaid stock grants issued to vendors $ - $ 72
Taxes accrued for repurchase of restricted shares $ 49 $ -
Investing
Preferred Stock Deemed Dividend $ 3,033 $ -
Excess consideration note $ - $ 6,822
Three Months Ended
March 31,
2020 2019
(unaudited)
Operating
Adoption of ASC 842 - right of use asset $ - $ 2,449
Adoption of ASC 842 - operating lease liability $ - $ (2,536 )
Taxes accrued for repurchase of restricted shares $ - $ 32
Financing
Accrued Financing costs $ 314 $ 53
Preferred Stock Deemed Dividend $ 3,033 $ -
16. EQUITY

Preferred Stock ~~Issuance~~
Issuance: Securities Purchase and Exchange Agreement

On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital ~~II, L.P., (“1315 Capital”),~~ and Ampersand 2018 Limited Partnership (“Ampersand” and, together with 1315 Capital, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $20.0 million in Series B ~~convertible preferred stock~~Preferred Stock of the Company, ~~par value $0.01 per share (the “Series B Preferred Stock”),~~ at an issuance price per share of $1,000. Pursuant to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase 19,000 shares of Series B Preferred Stock at an aggregate purchase price of $19.0 million and Ampersand agreed to purchase 1,000 shares of Series B Preferred Stock at an aggregate purchase price of $1.0 million.

In addition, the Company agreed to exchange $27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the “Series A Preferred Stock”), represented by 270 shares of Series A Preferred Stock with a stated value of $100,000 per share, which represents all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly issued shares of Series B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”). Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred Stock has a conversion price of $6.00 as compared to a conversion price of $8.00 on the Series A Preferred Stock, but did not include certain rights applicable to the Series A Preferred Stock, including a six-percent (6%) dividend and a conversion price adjustment for any failure by the Company to achieve a revenue target of $34.0 million in 2020 related to its ~~diagnostics business~~clinical services or a weighted-average anti-dilution adjustment. Under the terms of the Securities Purchase and Exchange Agreement, Ampersand also agreed to waive all dividends and weighted-average anti-dilution adjustments accrued to date on the Series A Preferred Stock.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)

A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $2.2 million, which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series B Preferred stock. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the ~~common stock~~Common Stock on January 15, 2020 of $6.79 per share and the effective conversion price per share of $6.00 multiplied by the number of shares of common stock issuable upon conversion. The Company fully amortized the beneficial conversion feature during the three months ended March 31, 2020 in accordance with GAAP. The beneficial conversion feature resulted in an increase in the loss attributable to common shareholders for the three months ended March 31, 2020 in the Condensed Consolidated Statement of Operations, as it ~~represents~~represented a deemed dividend to the preferred shareholders.

In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect.
ATM ~~program~~arrangement

On September 20, 2019, the Company entered into an Equity Distribution Agreement ~~(the “Agreement”)~~ with Oppenheimer & Co. Inc., as ~~sales agent (the “Agent”),~~Agent, pursuant to which the Company may, from time to time, issue and sell shares of its Common Stock, at an aggregate offering price of up to $4.8 million (the “Shares”) through the Agent. Under the terms of the Equity Distribution Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as ~~amended.~~amended (the “Securities Act”).

Subject to the terms and conditions of the Equity Distribution Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares and may, at any time, suspend sales under the Equity Distribution Agreement or terminate the Equity Distribution Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0% of the aggregate gross proceeds from the Shares sold. The Equity Distribution Agreement contains customary representations and warranties and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. As of ~~March 31,~~September 30, 2020, approximately 178,000 shares have been sold for net proceeds to the Company of approximately $0.7 million.

As a result of the January ~~15,~~10, 2020 Securities Purchase and Exchange Agreement, additional Shares may no longer be sold under the ATM arrangement without a majority approval by the holders of the Series B Preferred Stock in accordance with the Amended and Restated Investor Rights Agreement entered into on that date. In addition, if our common stock is delisted by Nasdaq due to our failure to meet minimum stockholders’ equity requirements, we may no longer be eligible to sell under the Equity Distribution Agreement as well. See Note 19, Subsequent Events. Further, upon the filing of our Form 10-K for the year ended December 31, 2020, we will no longer remain eligible to use Form S-3 and therefore we will lose our ability to sell Shares under the Equity Distribution Agreement.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
17. WARRANTS

Warrants outstanding and warrant activity for the ~~three-months~~three- and nine-months ended ~~March 31,~~September 30, 2020 are as follows:

Description Classification Exercise Price Expiration Date Warrants Issued Warrants Exercised Warrants Cancelled/ Expired Balance
December 31,
2019 Balance
March 31,
2020

Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 - - 85,500 85,500
RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 - - 10,000 10,000
Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 - (4,000 ) 53,500 53,500
Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 (567,286 ) - 870,214 870,214
Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 - - 15,000 15,000
Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 - - 320,000 320,000
Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 - - 65,434 65,434

1,990,934 (567,286 ) (4,000 ) 1,419,648 1,419,648
Description Classification Exercise Price Expiration Date Warrants Issued Balance December 31, 2019 Warrants Cancelled/Expired Balance September 30, 2020

Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 85,500
RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 10,000
Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 53,500
Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 870,214
Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 15,000 (15,000 ) -
Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 320,000
Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 65,434

1,990,934 1,419,648 (15,000 ) 1,404,648

18.
RECENT ACCOUNTING PRONOUNCEMENTS
Recently Adopted Accounting Guidance
In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which changes the accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. The update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs should be presented accordingly as other assets, current and non-current on the balance sheet and expensed over the term of the hosting arrangement. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies are required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements.
Accounting Pronouncements Pending Adoption

Standards not yet effective

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment is effective for annual periods beginning after December 15, 2020. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements.
INTERPACE BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular information in thousands, except per share amounts)
19. SUBSEQUENT EVENTS

~~Federal Stimulus Programs~~Change in ~~Connection with Coronavirus Pandemic~~
As of May 1, 2020, we received $2.1 million in advances under the Centers for Medicare & Medicaid Services (CMS) accelerated and advance payment program, as well as a $0.65 million grant from the Department of Health and Human Services (HSS). The CMS advance will be offset against future Medicare billings of the Company, and the HSS grant is subject to certain conditions regarding its use, including developing coronavirus and serology tests. These grants and advances require certain certifications by the Company and impose specific limitations on the use of the proceeds. Based on these restrictions and limitations, the Company is treating the $0.65 million HSS grant as restricted cash until we have clarity on how the funds can be utilized by the Company based on the specific requirements of the HSS. Furthermore, although the Company initially explored the possibility of requesting a loan under the Small Business Administration Paycheck Protection Program, we elected not to complete an application because we are not certain we meet certain criteria of the program.
During April and early May 2020, the Company made payments totaling $888,000 to CGI for funds withheld from the Excess Consideration Note to satisfy certain adjustments and indemnification obligations under the Asset Purchase Agreement. The funds used to satisfy this obligation were not included in cash and cash equivalents as of December 31, 2019 and March 31, 2020. These funds and the related liability were included in Other Current Assets and Other Accrued Expenses, respectively, as of those period ends, and the settlement of the liability had no net impact on the Company’s operating cash flow or liquidity.
~~Amendment to Morrisville, North Carolina lease~~Officers

On ~~June 3,~~November 23, 2020, ~~Interpace Pharma Solutions, Inc. (“IPS”),~~in connection with his retirement, Jack E. Stover announced his decision to resign as President, Chief Executive Officer, and member of the Board of Directors of the Company, effective December 1, 2020. On that same date, the Board appointed Mr. Thomas W. Burnell as the Company’s successor President and Chief Executive Officer and nominated and elected him as a ~~wholly-owned subsidiary~~member of the Board, in each case effective December 1, 2020.
In connection with the appointment as President and Chief Executive Officer, the Company entered into an employment agreement with ~~Southport Business Park Limited Partnership (“~~Mr. Burnell who will serve as Chief Executive Officer of the ~~Landlord”)~~Company for a term of three years, with automatic extension for one year renewal periods unless either the Company or Mr. Burnell elects not to ~~amend its Morrisville, North Carolina lease effective June 1, 2020 (the “Amendment”). This lease~~renew at least 60 days prior to the end of the then-current term. The Company agreed to pay to him a base salary of $425,000 annually during the initial term, with potential for increase after the first year of employment in the sole discretion of the Company’s Compensation and Management Development Committee. He is also eligible to receive additional annual incentive compensation with an annual target of up to 50% of the base salary. He was ~~originally~~also awarded 100,000 RSUs which vest in equal installments over three years and 125,000 performance based RSUs which are eligible to vest on the day following a 30 calendar day period in which, for each trading day of such period, a share of Common Stock has a closing per share price of at least $11.34
In connection with Mr. Stover’s resignation, the Company entered into a Separation and Consulting Agreement and General Release. The Stover Separation and Consulting Agreement supersedes the Stover Amended and Restated Employment Agreement. Under the terms of the Stover Separation and Consulting Agreement, the Company agrees to provide to Mr. Stover, upon fulfilment of certain conditions such as compliance with the Restrictive Covenants (as discussed below): (i) cash payments equal to $477,405, payable in equal installments over twelve months in accordance with the Company’s standard payroll practices; (ii) full acceleration of any non-qualified options and RSUs that are outstanding as of December 31, 2020 and that would have time-vested prior to December 31, 2022; (iii) a lump sum payment of $286,443, payable on ~~June 12, 2004~~the Company’s first payroll period of January 2022; and (iv) a fully vested nonqualified stock option to purchase 43,750 shares of Common Stock with a per-share exercise price of $6.00, exercisable until the tenth anniversary of the grant date and governed by the ~~Landlord~~terms of the Plan and ~~Cancer Genetics, Inc.,~~ the Company’s ~~predecessor-in-interest (the “Original Lease”)~~form of Stock Option Grant Notice and ~~was assigned to~~Stock Option Agreement thereunder
Financial Restatements
On January 19, 2021, the Company ~~on July 15,~~filed amended consolidated financial statements for the years ended December 31, 2019 ~~(the “Lease Assignment”). The Original Lease together~~and the quarters ended March 31, 2020 and June 30, 2020 with ~~all amendments, as assigned by~~ the ~~Lease Assignment constitutes~~SEC. As such, the ~~“Lease.” The Company re-affirmed its Guaranty of Lease, dated July 15, 2019,~~consolidated financial statements contained in the ~~Amendment, guaranteeing~~Company’s Annual Reports on Form 10-K for the ~~obligations~~years ended December 31, 2014, 2015, 2016, 2017, 2018, and 2019, as well as the consolidated financial statements contained in the Quarterly Reports on Form 10-Q for the each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020, should no longer be relied upon. The impact of ~~IPS under~~ the ~~Lease.~~restated financials is reflected in the consolidated financial statements issued herein. See our Explanatory Note in the beginning of this Form 10-Q for a summary of the financial impact.
Untimely SEC Filing and Nasdaq Notification of Compliance

The ~~Amendment provides~~Company was unable to timely file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020. On August 18, 2020, the Company was notified by Nasdaq that it was in non-compliance with Listing Rule 5250(c)(1), which requires the timely filing of periodic financial statements. On October 21, 2020, the Company received confirmation from Nasdaq that it regained compliance with the listing rule following the filing of the 10-Q for the period ended June 30, 2020 on October 19, 2020.
On November 17, 2020, the Company filed Form 12b-25 with the SEC, which stated that the Company was unable to file timely its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 due to the evaluation of its Barrett’s intangible asset for impairment and possible prior period adjustments to amortization expense. The Company could not complete its analysis by the SEC filing deadline. On November 18, 2020, the Company was notified by Nasdaq that it is in non-compliance with Listing Rule 5250(c)(1), which requires the timely filing of periodic financial statements. The Company was provided 60 days to submit its plan to show compliance with the filing requirement. Upon the filing of this Form 10-Q with the SEC, the Company believes it will have remedied the Nasdaq non-compliance issue due to the untimely filing.
Nasdaq Minimum Stockholders’ Equity Requirement
On October 21, 2020, the Company received notice from Nasdaq indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Nasdaq Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of approximately $1.7 million as reported in the 10-Q for the period ended June 30, 2020 was below the required minimum of $2.5 million. Due to the asset impairment and additional amortization expense reflected in the Company’s amended Form 10-K and Form 10-Q’s, the Company’s stockholders’ equity balance at September 30, 2020 was approximately ($21.8) million. The decrease in the Company’s stockholders’ equity resulting from the impairment and additional amortization expense will make it more difficult for the Company to comply with Nasdaq minimum stockholders’ equity requirements.
The Company was granted 45 calendar days, or through December 7, 2020, to submit to Nasdaq a plan to regain compliance with the listing requirement. If Nasdaq accepts the Company’s plan, Nasdaq may grant an extension of up to 180 calendar days from October 21, 2020, or through Tuesday, April 20, 2021, to regain compliance. If Nasdaq does not accept the ~~term~~Company’s plan, the Company will have the right to request a hearing before an independent Nasdaq Hearings Panel. A hearing request would stay any suspension or delisting action pending the conclusion of the ~~Lease,~~hearings process.
A plan was filed with Nasdaq in December 2020. However, there can be no assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance or maintain compliance with any other Nasdaq requirement in the future.
Second Amendment and Termination of SVB Loan Agreement
On October 19, 2020, the Company entered into the Second Amendment, which ~~consists of approximately 24,906 square feet utilized by IPS as laboratory and office space to provide its pharma solutions services. The~~amended the SVB Loan Agreement.
Under the terms of the ~~Lease were set to expire on May 31, 2020. Pursuant to~~Second Amendment, IPS joined the ~~Amendment, the term~~SVB Loan Agreement as a borrower and granted SVB a continuing lien upon and security interest in all of the ~~Lease was extended~~assets of IPS. Additionally, SVB waived certain existing or potential defaults under the SVB Loan Agreement, including the Company’s failure to meet certain financial covenants (specifically, the adjusted quick ratio requirement) for ~~ten additional years, commencing on June 1,~~the months ended July 31, 2020 and ~~continuing until May~~August 31, ~~2030 (the “Term”). The minimum rent per rentable square foot pursuant to~~2020 and the ~~Amendment is $14.10 from June 1, 2020 to May 31, 2021, with annual increases of 3%. The minimum rent during the first year~~Company’s reporting requirements under the ~~Amendment is $351,174.60, which is subject~~SVB Loan Agreement. SVB agreed to ~~a rent abatement consisting~~forebear from exercising its rights and remedies in connection with the Company’s reporting requirements until the earlier to occur of ~~six months~~(a) the occurrence of ~~rent forgiveness totaling $175,587, provided there is no outstanding uncured~~any event of default (as defined in the ~~Lease). The Company shall continue~~SVB Loan Agreement) other than any arising due to ~~pay to Landlord additional rent, representing~~ the Company’s ~~proportionate share of any direct expenses, as stipulated in the Lease.~~reporting requirements which were waived by SVB, or (b) December 31, 2020.

~~Pursuant~~The Second Amendment also modified the SVB Loan Agreement to, ~~the Amendment, the Company has two options to extend the Term for a period of five years each (the “Extended Terms”). Minimum rent during the Extended Terms, if such options are exercised~~among other things, a) exclude compliance by the Company ~~is subject~~with the adjusted quick ratio covenant requirement for the month of October 2020 as well as any month thereafter prior to ~~certain “market value” adjustments~~the Funding Date of the first Advance (in each case, as ~~provided for~~defined in the SVB Loan Agreement), if any, b) require delivery of certain insurance policy endorsements which have been provided by the Company, c) increase the maximum aggregate amount utilized for the issuance of the Letter of Credit by SVB in favor of the Company’s landlord for its Pittsburgh, Pennsylvania laboratory facility from $250,000 to $1,000,000, and d) increase the floating annual rate of interest on any principal amount outstanding under the Revolver to the greater of (A) one percent (1.0%) above the Prime Rate (as defined in the SVB Loan Agreement) and (B) four and one-quarter of one percent (4.25%). Prior to the Second Amendment, such interest accrued at a rate equal to one-half of one percent (0.50%) above the Prime Rate.
The Second Amendment provided that any future Credit Extension (as defined in the SVB Loan Agreement) by SVB to the Company will be made in SVB’s sole and absolute discretion. The Company agreed to reimburse SVB for all out-of-pocket reasonable and documented legal fees and expenses incurred in connection with the Second Amendment. ~~Also~~
On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.
Secured Promissory Notes
On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $3 million, and 1315 Capital, in the amount of $2 million, respectively (together, the “Notes”) and a related security agreement (the “Security Agreement”).
Ampersand holds 28,000 shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 4,666,666 shares of our Common Stock, and 1315 Capital holds 19,000 shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 3,166,668 shares of our Common Stock. On an as-converted basis, such shares would represent approximately 39.3% and 26.7% of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the ~~Amendment,~~terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company ~~has~~and Ampersand and 1315 Capital, they each have the ~~irrevocable~~ right to ~~terminate~~(1) approve certain of our actions, including our borrowing of money and (2) designate two directors to our Board of Directors. As a result, the ~~Lease~~Company considers the Notes and Security Agreement to be a related party transaction.
The rate of interest on ~~November~~the Notes is equal to eight percent (8.0%) per annum and their maturity date is the earlier of (a) June 30, ~~2025,~~2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as ~~well as~~defined in the Notes. No interest payments are due on ~~November 30, 2027, providing certain timely notification is given to Landlord, specified events occur (such as~~the Notes until their maturity date. All payments on the Notes are pari passu.
In connection with the Security Agreement, the Notes are secured by a ~~merger or sale~~first priority lien and security interest on substantially all of the ~~Company’s business),~~assets of the Company. Additionally, if a change of control of the Company occurs (as defined in the Notes) the Company is required to make a prepayment of the Notes in an amount equal to the unpaid principal amount, all accrued and ~~specified termination payments are made~~unpaid interest, and all other amounts payable under the Notes out of the net cash proceeds received by the Company from the consummation of the transactions related to ~~Landlord.~~such change of control. The Company may prepay the Notes in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed.
The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million dollars, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.
INTERPACE BIOSCIENCES, INC
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q ~~(Form 10-Q)~~ contains “forward-looking statements” within the meaning of Section 27A of the Securities Act ~~of 1933, as amended (the “Securities Act”),~~ and Section 21E of the Securities Exchange ~~Act.~~Act of 1934, as amended (the “Exchange Act”). Statements that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,” “could,” “may,” “will” or similar words and expressions. These forward-looking statements are contained throughout this Form 10-Q.

Forward-looking statements are only predictions and are not guarantees of future performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. These predictions are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement. Many of these factors are beyond our ability to control or predict. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. Such factors include, but are not limited to, the following:

● material adverse impact of Coronavirus (COVID-19) pandemic due to the slowdown in demand for our clinical services and pharma services, a reduction in samples received and testing volume and delayed third party collections and other factors;

● ~~we have~~the substantial doubt about our ability to continue as a going concern due to our history of operating losses, declining cash position and other liquidity factors, which in the absence of additional short term financing may cause us to cease or scale back operations;
● the limited revenue generated by our clinical services and pharma ~~services have generated limited revenue;~~services;

● we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability;

● our limited operating history, ~~and~~ the limited revenue generated from our business thus far and our fluctuating quarterly and annual revenue and operating results, including as a result of how we recognize revenue;

● our ability to timely file our SEC reports the failure of which could result in a delisting from Nasdaq, and loss of eligibility for certain registration statements and exemptions for resales;
● the failure to meet Nasdaq minimum stockholders’ equity requirement as of June 30, 2020 resulting in a letter from Nasdaq notifying us of the failure to meet this listing requirement and commencing procedures to potentially delist our Common Stock from Nasdaq, as well as the increased difficulty in meeting the minimum stockholders’ equity requirement as a result of the impairment charge, which delisting (if effected) could lead to a possible reduced stock price, potentially causing difficulty raising additional capital or debt, and also resulting in the loss of exemptions from various state securities laws;
● we generally depend on sales and reimbursements from our clinical services for more than 50% of our ~~revenue, and we will need~~revenue; the ability to continue to generate sufficient revenue from these and other products and/or solutions that we develop ~~or require~~in the future is important for our ability to ~~grow~~meet our ~~business;~~financial and other targets;

● we rely on third parties to process and transmit claims to payers for our clinical services, and any delay, data loss, or other disruption in processing or transmitting could have an adverse effect on our revenue and financial condition;

● our ability to utilize our commercial and operating experience to sell our clinical and pharma services;

● our ability to compete successfully in the markets that our clinical services and pharma services operate in;
INTERPACE BIOSCIENCES, INC
● our ability to obtain, retain and increase sufficient levels of ~~third party~~third-party reimbursement for our ~~molecular diagnostic~~clinical services tests in a changing and challenging reimbursement environment, including our current dependence on a concentrated number of third-party payers, ~~and~~ the lack of timeliness of their payments and the potential failure of such payments to ever occur;

● our billing practices and those of our third-party billing providers that can impact our ability to effectively bill and collect on claims for the sale of our clinical tests;

● our revenue recognition is based, in part, on our estimates for future collections and such estimates may prove to be incorrect;
● a deterioration in the collectability of our accounts receivable could have a material adverse effect on our business, financial condition and results of operations;

● ~~our~~the inability to finance our business on acceptable terms in the future may limit ~~our~~the ability to grow our business, develop and commercialize products and services, develop and commercialize new molecular ~~diagnostic~~clinical service solutions and technologies and expand our pharma ~~services;~~
● our ability to comply with financial covenants under our current line of credit facility and comply with our debt obligations and our ability to expand our working capital borrowing base to provide sufficient working capital financing during growth periods;services offerings;

● we have issued convertible preferred stock, and may issue additional convertible preferred stock in the future, ~~and the~~that includes terms ~~of our preferred stock~~that may dilute our ~~common stock;~~Common Stock;

● the concentration of our ownership in two private equity firms and their affiliates that control, on an as-converted basis, 66% of our fully diluted outstanding shares of ~~common stock~~Common Stock through their holdings of Series B ~~Convertible~~ Preferred Stock, ~~par value $0.01 per share (“Series B Preferred Stock”), and this concentration of ownership along with having authority for~~as well as their corresponding designation rights for a majority of our directors ~~will have~~and their right to approve certain of our actions, has resulted in these stockholders having a substantial influence on our business decisions;

● as billing for our clinical services tests is complex, ~~and~~ we must dedicate substantial time and resources to its invoicing process and are continuously taking measures to improve the ~~billing process to be paid for~~success of our ~~clinical services;~~accounts receivable collection activities;

● we depend onupon a ~~few~~small number of payers for a significant portion of our ~~revenue for our~~ clinical services and ifcould experience a decline in revenue, as well as a compromise to our commercial success, should one or more ~~significant~~of these payers ~~stops providing~~stop, delay or decrease reimbursement ~~or decreases the amount of reimbursement for our tests, our revenue could decline;~~payments;

● if payers do not provide reimbursement, rescind or modify their reimbursement policies or delay payments for our clinical services, we could experience a decline in revenue and our commercial success could be compromised;

● ~~developing~~the development of new tests, products and related services and solutions ~~includes~~typically requires a lengthy, complex and ~~complex~~costly process ~~with~~and development activities could prove unsuccessful or yield uncertain results;

● the effect of potential adverse findings, including potential laboratory shut downs, resulting from regulatory audits and inspections of our facilities, as well as our billing and payment practices, and the impact such ~~results~~adverse findings could have on our continuing business operations;
● a decline in demand for our clinical ~~services;~~services tests and/or our pharma services products;

● the ~~demand for~~failure of our ~~molecular diagnostic tests from physicians~~products and ~~patients;~~services to perform as forecast;

● ~~our products and services continuing to perform as expected;~~
● customer claims against us ~~for~~asserting inaccurate results from our ~~molecular diagnostic tests;~~clinical services tests or our pharma services products;
INTERPACE BIOSCIENCES, INC
● our obligations to make royalty and milestone payments to our licensors;

● our ability to obtain the data and samples that are needed to perform ~~sufficient~~the clinical studies that will enable us to ~~successfully~~ publish data demonstrating the clinical relevance and value of our ~~molecular diagnostic~~clinical services tests, including to support sufficient levels of ~~third party~~third-party reimbursement;

● our dependence on third parties for the supply of some of the materials used in our ~~molecular diagnostic tests~~clinical and pharma ~~services;~~services tests;

● our ability to successfully scale our operations, which could potentially result in delays in providing test results or ~~delays or reagent and supply~~in shortages for our tests and services;

● our ability to develop or acquire tests, services or solutions;
● the ability of our clinical services to enter into ~~additional clinical study~~ collaborations with highly regarded institutions;

● the ~~effect~~potential adverse impact of current and future laws, licensing requirements and ~~regulation have on~~governmental regulations upon our business operations, including but not limited to the ~~changing~~evolving U.S. ~~Food and Drug Administration~~regulatory environment ~~as it relates~~related to ~~molecular diagnostics and pharma services and~~ laboratory developed tests ~~(LDT’s);~~
● ~~changes in governmental regulations mandating price controls~~(“LDTs”), pricing of our tests and ~~limitations on~~services and patient access ~~to our products and services;~~limitations;

● if we fail to comply with Federal, State and foreign laboratory licensing requirements, we could lose the ability to perform our tests ~~or experience~~resulting in disruptions to our business;

● legislation reforming the U.S. healthcare system;

● a failure to comply with Federal and State laws and regulations pertaining to our ~~payment practices;~~billing practices could result in our being excluded from participation in Medicare, Medicaid or other governmental payer programs and/or significant monetary fines;

● our ability to comply with U.S. fraud and abuse laws, oras well as payer regulations, could result in our being excluded from participation in Medicare, Medicaid or other governmental payer ~~programs;~~programs and/or significant monetary fines;

● compliance with numerous statutes and regulations pertaining to our business;

● the effect of The Eliminating Kickbacks in Recovery Act of 2018 asto the extent that it ~~potentially impacts~~could negatively impact our ability to incentivize our sales ~~personnel appropriately;~~personnel;

● our ability to realize all of the anticipated benefits of the acquisition of our pharma services or those benefits, if any, taking longer to realize than ~~expected;~~was forecasted;

● if pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials decide not to use our tests and services, we may be unable to generate sufficient revenue to sustain our pharma services;

● if we fail to perform our pharma services in accordance with contractual and regulatory requirements, and ethical considerations, we could be subject to significant costs, ~~or liability;~~
● ~~our ability to compete~~legal liabilities and could experience a decline in ~~the markets our clinical services operate in;~~revenue;

● our ability to attract and retain key employees and management personnel;

● our reliance on our sales and marketing ~~forces~~activities for future business growth and our ability to continue to expand our sales and marketing ~~forces;~~activities;

● our limited experience in marketing and selling our products;
INTERPACE BIOSCIENCES, INC
● the ability of our clinical services tests to be successfully embraced by physicians and members of the medical community who have historically used traditional methods to diagnose gastrointestinal and endocrine cancers;

● ~~the~~our ability ~~of our molecular diagnostic tests~~ to effectively compete ~~successfully with physicians and members of the medical community who use traditional methods to diagnose gastrointestinal and endocrine cancers,~~against competitors ~~offering broader~~that offer product lines ~~outside of~~that extend beyond the ~~molecular diagnostic~~clinical services testing market, ~~and having~~that have greater brand recognition ~~than we do,~~ and ~~companies with~~that possess greater financial resources;

● our ability to license rights to use emerging technologies ~~in order~~that will enhance our ability to commercialize new products and services;

● the potential for liabilities or restraints on our ~~involvement in~~business as a result of unanticipated, future litigation, ~~against us~~as well as our potential inability to enforce legal judgments or ~~our ability to~~ collect ~~on judgements found~~monetary damages awarded in our favor;

● the ~~effect~~adverse impact of force majeure events, including but not limited to acts of nature, ~~seasonal results and~~ adverse weather conditions, hurricanes and floods, onepidemics and pandemics upon our business and the ability of our ~~suppliers;~~suppliers to provide us with critical materials and services;
● our use of hazardous materials;

● the susceptibility of our information systems to security breaches, loss of data and other disruptions;

● catastrophic loss of our laboratories;

● our ability to obtain and maintain sufficient qualified laboratory space to meet ~~our~~the processing needs ~~for all~~ of our business, as well as our ability to pass regulatory inspections and continue to be Clinical Laboratory Improvement Amendments (“CLIA”) and the College of American Pathologists ~~(“CAP”)~~ certified or accredited;

● compliance with the U.S. Foreign Corrupt Practices Act and anti-bribery laws;

● our ability to respond to rapid scientific changes in the areas in which we operate;

● our compliance with our license agreements and our ability to protect and defend our intellectual property rights;

● patent infringement claims against us;

● changes in U.S. and global patent law;

● tax reform legislation;

● stock dilution;

● changes in financial accounting standards or practices;

● exposure to international law, regulations and risk as a result of international expansion;

● we may acquire businesses or assets or make investments in other companies or testing, service or solution technologies that could ~~harm our operating~~negatively impact the results of business operations, dilute our stockholders’ ownership, increase our debts and/or cause us to incur significant ~~expense;~~expenses;

● the potential impact of existing and future contingent liabilities on our financial condition;

● the results of any future impairment testing for intangible assets as required under U.S. generally accepted accounting principles (“GAAP”);
INTERPACE BIOSCIENCES, INC
● our ability to remediate material weaknesses in internal controls and to maintain and implement effective internal controls over financial reporting, especially as we are consolidating operations;

● if our information technology or communications systems fail or we experience a significant interruption in their operation, our reputation, business and results of operations could be materially and adversely affected;

● the impact of future issuances of debt, common and preferred shares on stockholders’ interest and stock price;

● our ability to report financial results on a timely and accurate basis;

● our ability to manage our growth or unexpected declines;

●
the potential that the temporary equity classification of our preferred stock and the amortization and impairment of certain intangible assets set forth herein may trigger a Nasdaq compliance default for failure to meet minimum stockholder equity requirements which could result in a delisting of our common stock from Nasdaq leading to a possible reduced stock price; potential difficulty in raising additional capital or debt as well as loss of exemptions from various state securities laws which could hamper action plans to remediate such a Nasdaq compliance default;
● uncertainty regarding the regulatory obligations related to our receipt of $650,000 funding for ~~COVID~~COVID-19 testing;
● ~~our ability to rebuild our cost structure in anticipation of volume growth that does not happen as planned;~~

● the potential impact ~~on customers currently in~~of the relocation of our laboratory activities from Rutherford, NJ facility to our North Carolina facility upon ongoing customer clinical trials ~~in our Rutherford, NJ lab that we are now relocating~~if revalidation is delayed with respect to ~~North Carolina which may require revalidation in~~ the new site;

● the impact of ~~increased~~ costs ~~building expanded~~associated with expanding our laboratory capabilities in North Carolina in ~~anticipation~~connection with the relocation of ~~the move~~operations from Rutherford, NJ, ~~and~~as well as the potential for loss of customers ~~related to the move;~~as a result of this relocation;

● our ability to efficiently execute and complete the planned laboratory ~~move~~transition from Rutherford, NJ to North Carolina on a timely basis and within our forecasted costs;

● ~~the risk of~~potential loss of personnel that are uniquely qualified to perform the breadth of specialty testing and lab applications necessary for developing customized assays in our pharma ~~solutions business;~~services;
● potential legal liabilities related to our employees, contractors and other third parties asserting claims for damages arising from workplace exposure to certain infectious agents, including but not limited to the COVID-19 virus;
● the possibility that we may have to cease laboratory operations at one or more facilities for an undefined period of time due to the contraction of COVID-19 by persons that have been in such facilities, resulting in our inability to satisfy contractual obligations, a loss of revenue and other potential legal liabilities;
● certain payors may decline to reimburse us for services rendered and billed using new billing codes currently in use with Medicare;
● the inability to charge and collect payment for the Company’s serology antibody ELISA test for COVID-19 or the inability to coordinate the technology with a polymerase chain reaction test;
● the inability to raise capital in the future under the terms of our preferred stock arrangement could result in a Nasdaq market delisting and possibly in the Company seeking creditor protection pursuant to U.S. bankruptcy laws;
● the inability by the Company to consolidate its multiple LIM’s programs into one functioning LIM’s program in the North Carolina laboratory could negatively impact the operations of our pharma services;

● the risk of a breach of proprietary or confidential data, regulated data, and personal information of employees, customers and others; successful breaches, employee malfeasance, or human or technological error that could result in, unauthorized access to, disclosure, modification, misuse, loss, or destruction of company, customer, or other third party data or systems; theft of sensitive, regulated, or confidential data including personal information and intellectual property; the loss of access to critical data or systems through ransomware, destructive attacks or other means; and business delays, service or system disruptions or denials of service, as well as legal consequences under Federal, state and other applicable laws and regulations;
● the risk and cost associated with whistleblower threats, interventions and lawsuits on our business and the cost of responding to such matters;
● our ability to respond to rapid scientific change;
● the risk of liability in conducting clinical trials and the sufficiency of our insurance to cover such claims;
● our ability to implement our business strategy;
● Food and Drug Administration (“FDA”) regulation of LDTs;
● our ability to integrate future acquisitions and costs related to such acquisitions;
● our ability to hire and retain sufficient managerial, sales, ~~reps fully reengaging with customers after reducing physical visits by~~clinical and other personnel to meet our ~~commercial team during the pandemic.~~needs; and
● our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure.
INTERPACE BIOSCIENCES, INC
Please see Part I – Item 1A – “Risk Factors” in our Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on April 22, 2020, as amended on May 29, 2020 and January 19, 2021, as well as other documents we file with the SEC from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements discussed in this Form 10-Q. Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

OVERVIEW

We ~~are an emerging leader in enabling precision medicine principally in oncology by offering~~provide complex molecular analysis for the early diagnosis and treatment of certain cancers and supporting the development of targeted therapeutics. Though our clinical and pharma services, we offer specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic ~~applications through our~~applications. Our clinical services ~~and pharma services. Through our clinical services, we~~ enable physicians to personalize the clinical management of each ~~individual~~ patient by providing genomic information that allows them to better diagnose ~~monitor~~certain cancers and ~~inform cancer treatment.~~individualize patient treatments. Our ~~clinical services provide clinically useful~~proprietary molecular diagnostic tests, bioinformatics and pathology services ~~for evaluating risk of cancer by leveraging~~leverage the latest ~~technology in~~ personalized medicine ~~for improved~~technologies in order to improve patient diagnosis and management.
Through our pharma services, we ~~develop, commercialize and provide~~offer an extensive suite of molecular- and biomarker-based tests and services ~~and~~that provide ~~companies with~~unique, customized solutions for patient stratification and treatment ~~selection through an extensive suite of molecular~~selection. Our tests and ~~biomarker-based testing~~ services include DNA- and RNA- extraction, ~~and~~ customized assay development and trial design consultation. Our pharma services ~~provide~~offerings also include pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and ~~biotech industries and advances personalized medicine by partnering~~biotechnology industries. Through collaboration with pharmaceutical, academic and technology leaders, ~~to effectively integrate~~we are investing in innovations that will advance personalized medicine by better integrating pharmacogenomics into the drug development process and clinical trial ~~programs with the goals of delivering~~programs. Our goal is to help deliver safer, more effective drugs to market more quickly, ~~and~~while also improving patient care.

During fiscal 2019, in connection with the acquisition of our ~~pharma services, we raised~~Pharma Services, an affiliate of Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27 million ~~with Ampersand, a diagnostic laboratory private equity investor.~~in us in exchange for two tranches of newly issued convertible preferred stock. This was followed in 2020 by ~~raising an additional $20 million in early 2020~~agreements with investors, led by 1315 Capital, another sophisticated private equity ~~investor.~~investor, to invest an additional $20 million in us. We believe that the combination of our clinical services and acquired pharma services uniquely positions us for growth and expansion in the fast-growing biopharma sector, where we can provide our unique diagnostic capabilities to a broad customer base.

Impact of COVID-19 pandemic

We have taken what we believe are ~~all~~ necessary precautions to safeguard our employees from the ~~Coronavirus (COVID-19)~~COVID-19 pandemic. We ~~are following~~continue to follow CDC guidance and the recommendations and restrictions provided by state and local ~~restrictions. All~~authorities. The majority of our employees who do not work in a lab setting are currently able to successfully work remotely. While a number of employees were furloughed most have returned to work. Our labs require in-person staffing and we have been onable to continue to operate our labs, minimizing infection risk to lab staff through a ~~telecommunication work arrangement. Our employees in the lab are wearing what we believe is~~combination of social distancing and appropriate protective ~~gear.~~equipment. There can be no assurance, however, that key employees will not become ill or that we will able to continue to operate our ~~labs. We have furloughed a number of employees as a result of reductions in customer demand and we have closed our administrative offices. Our~~ labs require in-person staffing and as of the date of this report, we have been able to successfully operate our labs though a combination of social distancing, managing lab scheduling and protective equipment. Our management, finance staff and sales personnel have generally been able to successfully work remotely. As of June 15, 2020 we began allowing general and administrative staff to return to their respective offices on a limited basis.successfully.
INTERPACE BIOSCIENCES, INC

The ~~extent to which~~continuing impact that the COVID-19 pandemic ~~impacts~~will have on our operations, ~~continues to depend on future developments, which are~~including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time, and include the duration, severity and scope of the outbreak and the actions taken to contain or treat the coronavirus outbreak. In particular, the continued spread of the coronavirus globally has adversely affecting global economies and financial markets resulting in an economic downturn which could materially and adversely impact our operations including, without limitation, the functioning of our laboratories, the availability of supplies including reagents, the progress and data collection of our pharma services, customer demand and travel and employee health and availability.
Wetime. Accordingly, we believe that the COVID-19 pandemic ~~will also~~could continue to adversely impact our results of operations, cash flows and financial condition for the second quarter of fiscal 2020 and possibly beyond. Our fiscal 2020 first quarter revenue was impacted by lower than expected clinical service volume throughout March 2020, which we believe has resulted from the temporary reduction in non-essential testing procedures in connection with the COVID-19 pandemic. Further, we did reduce overall costs to match the lower volumes in the ~~labs.~~
However, as of the date of this Report, our overall business is still down approximately 30% from our run rate before the pandemic. We have continued to add resources to support the increased volume consistent with the changing environment. However, as we rebuild our cost structure to support the improved volume, there is risk that the anticipated volume growth will not materialize as planned and we will be required to adjust accordingly.future.

To optimize the operations of laboratory operations within our pharma services, ~~lab operations~~ we are transitioning ~~lab work~~activities from the Rutherford, NJ facility to our ~~facility in~~ Morrisville, ~~NC.~~NC facility. We ~~will be~~are investing several million dollars to facilitate this relocation, including but not limited to the ~~move,~~ transfer of personnel, ~~build out facilities~~expansion of the Morrisville facility and ~~validate~~validation of transferred processes over the next several months. We believe that this investment ~~and transition~~ will result in ~~reduced~~a reduction in future operating ~~costs in the future:~~costs; however, ~~there~~it is ~~no guarantee~~not certain whether we will ~~be as successful with~~successfully implement the ~~move~~relocation or whether the ~~benefits expected thereof as we currently plan.~~transition will produce the predicted financial benefits.

All of our ~~labs~~laboratories are currently ~~operating~~in operation and, ~~we believe we~~in our view, are appropriately staffed for ~~the volume of work. At this time,~~current volumes. While we do not anticipate any ~~lab~~laboratory closures at this time beyond periodic, temporary work stoppages ~~from time to time~~ to clean and disinfect the ~~labs. Lab~~labs, this could change in the future based upon conditions caused by the pandemic. Further, while we have acquired additional inventories of laboratory supplies, including reagents, ~~have been secured to mitigate any potential~~it is possible that we could experience supply chain ~~issues~~shortages if the pandemic continues for a prolonged period and/or if one or more suppliers is unable to continue to provide us with inventory. For the foreseeable future, ~~and~~however, we ~~are~~do not ~~observing any shortages due to~~anticipate supply chain ~~issues. Our third party~~shortages of critical supplies or delays from our third-party clinical services billing and collections ~~company has taken steps~~company. We continue to monitor the actual and potential impact of the pandemic upon our operations and will continue ~~operations remotely. There have been indications that payer processing may slow down but so far there has been little or no material impact~~ to ~~our collections.~~do so.

~~As of May 2020, we are in the process of launching~~We have developed and validated a ~~new product line of~~serology antibody ELISA testing for ~~the~~ COVID-19 ~~virus. Validation is complete; we~~at our CLIA lab in Pittsburgh, PA. We have acquired acceptable kits and reference samples and are now offering this ~~testing~~test to ~~our~~ employees and select customers. ~~The~~Our serological, or antibody test measures ~~the amount of~~ antibodies present in the blood. In response to an infection, such as COVID-19, the body develops an overall immune response to fight the infection. One component of the immune system’s response is the development of antibodies that attach to the virus and help eliminate it. Antibody tests detect the body’s immune response to the infection caused by the virus rather than detecting the virus itself. The FDA has issued guidance allowing companies to market serological tests that have been validated following notification to FDA. Validated antibody tests offered under the policy should, among other things, include inlanguage within test reports ~~language explaining~~cautioning that negative results do not rule out COVID-19 infection and that follow-up testing with a molecular diagnostic should be considered to rule out infection. ~~There is no guarantee that we will be successful in realizing~~We do not expect to generate any significant revenue ~~or benefit~~ from these ~~efforts.~~efforts at this time.
INTERPACE BIOSCIENCES, INC

Additional Reimbursement Coverage and Price Increase During 2020 and 2021

Reimbursement progress is key for ~~any molecular diagnostic company.~~us. We have been successful to date in expanding both the scope and amount of product reimbursement for our clinical services in 2020. Examples of our ~~products in 2020. Specifically, the most significant~~ progress ~~we have made regarding payers to date in 2020 is as follows:~~include:

● In February 2020, we announced an increase in Medicare reimbursement for our ThyraMIR^® test from $1,800 to $3,000, retroactive to January 1, 2020, reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices.

● In March 2020, we announced ~~we had entered into a contract~~an agreement with Blue Cross Blue Shield of Massachusetts ~~making~~under which ThyGeNEXT^®and ThyraMIR^® tests are now covered in-network services for their more than 3 million members in Massachusetts and across New England.
● In March 2020, we announced ~~we had entered into a contract~~an agreement with CareFirst Blue Cross Blue Shield ~~making ThyGeNEXT®~~that makes ThyGeNEXT^® and ~~ThyraMIR®~~ ThyraMIR^®tests covered in-network services for their more than 3.3 million members in Maryland, Washington, D.C., and Northern Virginia.

● In March 2020, we announced we had entered into a contract with Premera Blue Cross, making ~~ThyGeNEXT®~~ThyGeNEXT^® and ~~ThyraMIR®~~ ThyraMIR^®tests covered in-network services for their more than 2 million members in Washington State and Alaska.

● In April 2020, we executed an agreement with Avalon Healthcare Solutions (Avalon), a laboratory benefit manager representing numerous health plans. ~~Our~~This agreement ~~with Avalon offers us~~provides in-network status for our products to approximately 5.8 million lives covered by the following health plans: Blue Cross Blue Shield North Carolina, South Carolina, Kansas City and Vermont, and Capital Blue Cross of Central Pennsylvania.

● In April 2020, we executed a contract with Blue Cross of Idaho making ~~ThyGeNEXT®~~ThyGeNEXT^® and ~~ThyraMIR®~~ThyraMIR^® tests covered in-network services for their more than ~~576 thousand~~576,000 members.

● In May 2020, we executed a contract with Blue Cross Blue Shield of Wyoming.
●
In July 2020, we announced that our peer reviewed manuscript, describing results from a seminal clinical validation study of the combination of ThyGeNEXT^® and ThyraMIR^®, was accepted for publication in the highly respected journal Diagnostic Cytopathology and also accepted as a podium presentation for the American Society of Cytopathology (ASC) Annual Meeting. On August 7, 2020 this publication was made available on-line.
● In December 2020, we executed an agreement with Regence Blue Cross Blue Shield of Washington State, Utah, Oregon, and Idaho.
● In December 2020, we executed an agreement with HealthNow New York, parent company of Blue Cross Blue Shield of Western New York, and Blue Cross Blue Shield of Northeastern New York.
● In December, 2020, we executed an agreement with Florida Blue/Blue Cross Blue Shield of Florida, which was effective January 1, 2021.
● In December 2020, Medicare increased pricing for our ThyGeNEXT^® test from $600 to $2,900. We began realizing reimbursement at the higher rate starting in January 2021.

Revenue Recognition

Clinical services derive its revenues from the performance of its proprietary assays or tests. ~~The Company’s~~Our performance obligation is fulfilled upon completion, review and release of test results to the ~~customer. The Company subsequently bills~~customer, at which time we bill third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based onupon the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test ~~offered by the Company.~~offered. To the extent that the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, ~~the Company estimates~~we estimate the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

~~For our clinical services, we regularly review the~~The ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates are regularly reviewed and we adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we adjust the estimates of contractual allowances, which ~~would affect~~affects net revenue in the period such variances become known.

~~For~~With respect to our pharma services, ~~customers,~~customer performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

Deferred Revenue

For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.

Cost of Revenue

Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all ~~labor related~~labor-related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.

INTERPACE BIOSCIENCES, INC
CONDENSED CONSOLIDATED RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, certain statements of operations ~~data and have been restated to reflect the additional amortization expense and certain other adjustments.~~data. The trends illustrated in this table may not be indicative of future results.

Condensed Consolidated Results of Continuing Operations for the Quarter Ended ~~March 31,~~September 30, 2020 Compared to the Quarter Ended ~~March 31,~~September 30, 2019 (unaudited, in thousands)

As Restated
Three Months Ended March 31, Three Months Ended September 30,
2020 2020 2019 2019 2020 2020 2019 2019

Revenue, net $ 9,059 100.0 % $ 6,010 100.0 % $ 8,248 100.0 % $ 7,725 100.0 %
Cost of revenue 6,113 67.5 % 2,622 43.6 % 5,194 63.0 % 4,835 62.6 %
Gross profit 2,946 32.5 % 3,388 56.4 % 3,054 37.0 % 2,890 37.4 %
Operating expenses:
Sales and marketing 2,481 27.4 % 2,411 40.1 % 2,699 32.7 % 2,757 35.7 %
Research and development 809 8.9 % 528 8.8 % 763 9.3 % 857 11.1 %
General and administrative 4,893 54.0 % 2,735 45.5 % 4,482 54.3 % 4,492 58.1 %
Acquisition related amortization expense 1,115 12.3 % 897 14.9 %
Acquisition related expense - 0.0 % 838 10.8 %
Acquisition amortization expense 1,115 13.5 % 1,079 14.0 %
Total operating expenses 9,298 102.6 % 6,571 109.3 % 9,059 109.8 % 10,023 129.7 %

Operating loss (6,352 ) -70.1 % (3,183 ) -53.0 % (6,005 ) -72.8 % (7,133 ) -92.3 %
Interest accretion (109 ) -1.2 % (129 ) -2.1 % (138 ) -1.7 % (111 ) -1.4 %
Other income (expense), net 47 0.5 % 48 0.8 % (12 ) -0.1 % (135 ) -1.7 %
Loss from continuing operations before tax (6,414 ) -70.8 % (3,264 ) -54.3 % (6,155 ) -74.6 % (7,379 ) -95.5 %
Provision for income taxes 15 0.2 % 5 0.1 % 14 0.2 % 9 0.1 %
Loss from continuing operations (6,429 ) -71.0 % (3,269 ) -54.4 % (6,169 ) -74.8 % (7,388 ) -95.6 %

Loss from discontinued operations, net of tax (65 ) -0.7 % (57 ) -0.9 % (65 ) -0.8 % (58 ) -0.8 %

Net loss $ (6,494 ) -71.7 % $ (3,326 ) -55.3 % $ (6,234 ) -75.6 % $ (7,446 ) -96.4 %
Revenue, net

Consolidated revenue, net for the three months ended ~~March 31,~~September 30, 2020 increased by ~~$3.0~~$0.5 million, or ~~51%~~7%, to ~~$9.1~~$8.2 million, compared to $7.7 million for the three months ended September 30, 2019. The increase in net revenue was largely driven by higher clinical volumes and increased reimbursement rates.
Cost of revenue
Consolidated cost of revenue for the three months ended September 30, 2020 was $5.2 million, as compared to $4.8 million for the three months ended September 30, 2019. As a percentage of revenue, cost of revenue was approximately 63% for both the three months ended September 30, 3020 and September 30, 2019.
INTERPACE BIOSCIENCES, INC
Gross profit
Consolidated gross profit was approximately $3.1 million for the three months ended September 30, 2020 and $2.9 million for the three months ended September 30, 2019. The gross profit percentage was approximately 37% for both the three months ended September 30, 3020 and September 30, 2019.
Sales and marketing expense
Sales and marketing expense was approximately $2.7 million for the three months ended September 30, 2020 and $2.8 million for the three months ended September 30, 2019. As a percentage of revenue, sales and marketing expense decreased to 33% from 36% in the comparable prior year period.
Research and development
Research and development expense was $0.8 million for the three months ended September 30, 2020 and $0.9 million for the three months ended September 30, 2019 due to lower professional services costs in the quarter. As a percentage of revenue, research and development expense decreased to 9% from 11% in the comparable prior year period.
General and administrative
General and administrative expense was approximately $4.5 million for both the three months ended September 30, 2020 and for the three months ended September 30, 2019.
Acquisition related expense
During the three months ended September 30, 2019 we incurred approximately $0.8 million in expenses related to the acquisition of our pharma services in 2019. We did not incur any acquisition related expenses during the three months ended September 30, 2020.
Acquisition amortization expense
During the three months ended September 30, 2020 and September 30, 2019, we recorded amortization expense of approximately $1.1 million, respectively in both periods, which is related to intangible assets associated with prior acquisitions.
Operating loss
Operating loss from continuing operations was $6.0 million for the three months ended ~~March 31,~~September 30, 2020 as compared to $7.1 million for the three months ended September 30, 2019. The operating loss for 2020 included a $1.2 million benefit in the reversal of prior year’s bonus accrual. The operating loss for the three months ended September 30, 2019 also included $0.8 million in acquisition related expenses.
Provision for income taxes
Income tax expense was approximately $14,000 for the three months ended September 30, 2020 and $9,000 for the three months ended September 30, 2019. Income tax expense for both periods was primarily driven by minimum state and local taxes.
INTERPACE BIOSCIENCES, INC
Loss from discontinued operations, net of tax
We had a loss from discontinued operations of approximately $0.1 million for the three months ended September 30, 2020 and a loss from discontinued operations of approximately $0.1 million for the three months ended September 30, 2019.
Condensed Consolidated Results of Continuing Operations for the Nine-Months Ended September 30, 2020 Compared to the Nine-Months Ended September 30, 2019 (unaudited, in thousands)
Nine Months Ended September 30,
2020 2020 2019 2019

Revenue, net $ 22,752 100.0 % $ 20,005 100.0 %
Cost of revenue 15,156 66.6 % 10,489 52.4 %
Gross profit 7,596 33.4 % 9,516 47.6 %
Operating expenses:
Sales and marketing 6,776 29.8 % 8,127 40.6 %
Research and development 2,123 9.3 % 2,032 10.2 %
General and administrative 13,481 59.3 % 9,613 48.1 %
Acquisition related expense - 0.0 % 2,534 12.7 %
Acquisition amortization expense 3,346 14.7 % 2,874 14.4 %
Total operating expenses 25,726 113.1 % 25,180 125.9 %

Operating loss (18,130 ) -79.7 % (15,664 ) -78.3 %
Interest accretion (414 ) -1.8 % (331 ) -1.7 %
Other (expense) income, net 473 2.1 % (12 ) -0.1 %
Loss from continuing operations before tax (18,071 ) -79.4 % (16,007 ) -80.0 %
Provision for income taxes 43 0.2 % 19 0.1 %
Loss from continuing operations (18,114 ) -79.6 % (16,026 ) -80.1 %

Loss from discontinued operations, net of tax (194 ) -0.9 % (51 ) -0.3 %

Net loss $ (18,308 ) -80.5 % $ (16,077 ) -80.4 %
Revenue, net
Consolidated revenue, net for the nine months ended September 30, 2020 increased by $2.7 million, or 14%, to $22.8 million, compared to $20.0 million for the nine months ended September 30, 2019. This increase was principally attributable to our acquisition of our pharma services ~~business~~ in 2019. Our ~~first quarter~~nine months revenue ~~was~~has been impacted by lower than expected clinical service volume ~~throughout~~from March through September 2020, which we believe has resulted from the temporary reduction in non-essential testing procedures in connection with the COVID-19 pandemic.

Cost of revenue

Consolidated cost of revenue for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 was ~~$6.1~~$15.2 million, as compared to ~~$2.6~~$10.5 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. As a percentage of revenue, cost of revenue increased to ~~66%~~67% for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 as compared to ~~44%~~52% in the comparable same period in 2019. This increase as a percentage of revenue can be primarily attributed to the lower margins associated with our pharma services and the decrease in revenue within clinical services.
INTERPACE BIOSCIENCES, INC

Gross profit

Consolidated gross profit was approximately ~~$2.9~~$7.6 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 and ~~$3.4~~$9.5 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. The gross profit percentage decreased from ~~56%~~48% in the first ~~quarter~~nine months of 2019 to 33% for the first ~~quarter~~nine months of 2020. This decrease can be attributed to the lower margins associated with our pharma services, as mentioned above, and the reduction in net revenue from clinical services.
Sales and marketing expense

Sales and marketing expense was ~~$2.5~~$6.8 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2020, or ~~27%~~30% as a percentage of net revenue. For the ~~three~~nine months ended ~~March 31,~~September 30, 2019, sales and marketing expense was ~~$2.4~~$8.1 million, or ~~40%~~41% as a percentage of net revenue. The ~~increase~~decrease in sales and marketing expense primarily reflects the ~~addition~~slowdown of sales ~~and marketing costs associated with pharma services.~~activity for clinical services due to the pandemic.

Research and development

Research and development expense was ~~$0.8~~$2.1 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 and ~~$0.5~~$2.0 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. ~~The increase was primarily attributable to costs associated with the acquired pharma services.~~ As a percentage of revenue, research and development expense ~~stayed the same at~~was approximately 9% ~~in both periods.~~for the nine months ended September 30, 2020 and 10% for the nine months ended September 30, 2019.

General and administrative

General and administrative expense for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 was ~~$4.9~~$13.5 million as compared to ~~$2.7~~$9.6 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. The increase was primarily attributable to costs associated with the acquired pharma services.

Acquisition related expense
During the nine months ended September 30, 2019 we incurred approximately $2.5 million in expenses related to the acquisition of our pharma services in 2019. We did not incur any acquisition related expenses during the nine months ended September 30, 2020.
Acquisition amortization expense

During the ~~three~~nine months ended ~~March 31,~~September 30, 2020 and ~~March 31,~~September 30, 2019, we recorded amortization expense of ~~$1.1~~$3.3 million and ~~$0.9~~$2.9 million, respectively, which is related to intangible assets associated with prior acquisitions. The increase is related to our acquisition of our pharma services in 2019 and the associated intangible assets.

Operating loss

Operating loss from continuing operations was ~~$6.4~~$18.1 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 as compared to ~~$3.2~~$15.7 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. The increase can be attributed to the operating loss associated with our pharma services as well as the reduced revenue and gross profit in our clinical services.

Provision for income taxes

Income tax expense was approximately ~~$15,000~~$43,000 for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 and ~~$5,000~~$19,000 for the ~~three~~nine months ended ~~March 31,~~September 30, 2019. Income tax expense for both periods was primarily driven by minimum state and local taxes.

Loss from discontinued operations, net of tax

We had a loss from discontinued operations of approximately $0.2 million for the nine months ended September 30, 2020 and a loss from discontinued operations of approximately $0.1 million for ~~both~~ the ~~three~~nine months ended ~~March 31, 2020 and March 31,~~September 30, 2019.

41
INTERPACE BIOSCIENCES, INC

LIQUIDITY AND CAPITAL RESOURCES

For the ~~three~~nine months ended ~~March 31,~~September 30, 2020, we had an operating loss of ~~$6.4~~$18.1 million. As of ~~March 31,~~September 30, 2020, we had cash and cash equivalents of ~~$13.4~~$5.3 million, total current assets of ~~$28.1~~$17.6 million and current liabilities of ~~$15.7~~$15.6 million. ~~Currently, the Company has no further availability~~As of January 15, 2021, we had approximately $6.1 million of cash on ~~its credit facility, but is in the process~~hand, net of ~~completing an agreement with SVB to expand the credit facility. No assurance can be given that such an expansion agreement will be entered into.~~restricted cash.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2020, net cash used in operating activities was ~~$7.1~~$12.4 million. The main component of cash used in operating activities was our net loss of ~~$6.5~~$18.3 million which was partially offset by non-cash expenses of $4.9 million. During the ~~three~~nine months ended ~~March 31,~~September 30, 2019, net cash used in operating activities was ~~$3.0~~$12.6 million, all but $0.03 million of which was used in continuing operations. The main component of cash used in operating activities during the ~~three~~nine months ended ~~March 31,~~September 30, 2019 was the net loss of ~~$3.4~~$16.1 million.

For the ~~three~~nine months ended ~~March 31,~~September 30, 2020, ~~there~~cash used in investing activities was $1.3 million, primarily related to capital expenditures associated with the moving of our Rutherford, New Jersey lab to North Carolina. For the nine months ended September 30, 2019, cash used in investing activities was $13.9 million, $13.8 million of which was used in our acquisition of the pharma services business.
For the nine months ended September 30, 2020, cash provided from financing activities ~~of $18.2~~was $16.7 million, ~~$19.5~~$19.2 million which resulted from the issuance of ~~Preferred Stock~~preferred stock in January 2020 and $0.4 million from sales of ~~common stock, and was~~Common Stock, partially offset by ~~$1.8~~the repayment of $3.0 million ~~in a net repayment~~ of borrowed funds under our ~~revolving line of credit with SVB.~~Revolver. For the ~~three~~nine months ended ~~March 31,~~September 30, 2019, ~~there was~~ cash provided from financing activities ofwas $22.8 million, $6.0 million of which resulted from the issuance of ~~common stock~~Common Stock in our underwritten public offering completed in January ~~2019.~~2019, $13.1 million of which resulted from the issuance of preferred stock in July 2019, and $3.7 million of which resulted from our draw down of funds under our Revolver.

On January 5, 2021, the Company terminated its SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company. See Note 19, Subsequent Events.
On January 7, 2021, the Company entered into secured promissory notes in the amount of $3 million and $2 million with Ampersand and 1315 Capital, respectively. See Note 19, Subsequent Events.
As of July 31, 2020, the Company was in violation of a financial covenant under the SVB Loan Agreement. Additionally, due to the untimely filing of our second quarter Form 10-Q with the SEC, the Company was in default under the SVB Loan Agreement. During September 2020, the Company paid down the outstanding Revolver balance of $3.4 million in full and transferred $0.35 million into a restricted cash money market account with SVB to serve as collateral for the Company’s letters of credit supporting its facilities. Prior to September 2020, the collateral for the letters of credit was accounted for as a reduction in the availability under the Revolver. As of September 30, 2020, and through the date of termination of the SVB Loan Agreement, there was no balance outstanding on the Revolver. SVB agreed to forebear from exercising its rights and remedies with respect to the default on October 19, 2020 and the Company was in compliance with the terms of the SVB Loan Agreement through the date of its termination.
During October 2020, the Company had amended the SVB Loan Agreement, adding the Company’s subsidiary, IPS, as a borrower thereunder and granted SVB a continuing lien upon and security interest in all of the assets of IPS (See Note 19, Subsequent Events). Under the original terms of the SVB Loan Agreement, the Company covenanted to maintain at all times an Adjusted Quick Ratio of at least 1.15 to 1.0. SVB waived the Company’s failure to comply with such requirement for the months ended July 31, 2020 and August 31, 2020 and agreed to forebear financial covenant testing while the Revolver was not drawn. The Company did not draw down on the Revolver from the date of this waiver through the termination of the SVB Loan Agreement.
In September 2019, we entered into the Equity Distribution Agreement ~~(the “Agreement”)~~ with Oppenheimer & Co. Inc., as ~~sales agent (the “Agent”),~~Agent, pursuant to which we may, from time to time, issue and sell shares of our ~~common stock~~Common Stock in an aggregate offering price of up to ~~$4.8~~$3.7 million through the Agent. ~~See Note 16,~~ ~~Equity~~ ofDuring the ~~notes to the financial statements for more details. In January~~nine months ended September 30, 2020, ~~80,341~~approximately 178,000 shares ~~(as adjusted for the reverse stock split)~~ of common stock were sold for net proceeds of approximately ~~$0.4~~$0.7 million. As a result of the preferred shares transaction mentioned below, additional shares may no longer be sold under the ATM arrangement without a majority approval by the holders of the preferred shares. In addition, if our Common Stock is delisted by Nasdaq due to our failure to meet minimum stockholders’ equity requirements, we may no longer be eligible to sell under the Equity Distribution Agreement as well.Further, upon the filing of our Form 10-K for the year ended December 31, 2020, we will no longer remain eligible to use Form S-3 and therefore we will lose our ability to sell Shares under the Equity Distribution Agreement.

As of March 31, 2020, the Company had drawn $1.2 million of the $3.75 million of available funds under its Revolving Line with SVB. As of June 17, 2020, we had no funds available on the Revolving Line because we were fully drawn.
In January 2020, we sold 20,000 preferred shares to investors, led by 1315 Capital, for net proceeds of approximately ~~$19.5~~$19.2 million; see Note 16, Equity of the ~~footnotes~~notes to the financial statements for more detail.

See Note 1, Overview, of the notes to the financial statements, regarding the potential adverse impact of the COVID-19 pandemic on our results of operations, cash flows and financial condition for the third quarter of fiscal 2020 and possibly beyond.
During April 2020, the Company applied for various federal stimulus grants and advances made available under Title 1 of the CARES Act. As of ~~June 17,~~September 30, 2020, we received $2.1 million in advances under the ~~Centers for Medicare & Medicaid Services (CMS)~~CMS accelerated and advance payment program, as well as a $0.65 million grant from ~~the Department of Health and Human Services (HSS).~~HHS. The CMS advance will be offset against future Medicare billings of the Company, and we applied the ~~HSS~~HHS grant ~~is subject~~in its entirety towards qualified second quarter expenses. These expenses related to ~~certain conditions regarding its use,~~lab equipment and supplies purchased to prevent, prepare for, and respond to coronavirus, including ~~developing~~development of coronavirus and serology ~~tests. These grants and advances require certain certifications~~tests, as well as expenses that would have been covered by revenue lost to coronavirus during the Company and impose specific limitations on the use of the proceeds. Based on these restrictions and limitations, the Company is treating the $0.65 million HSS grant as restricted cash until we have clarity on how the funds can be utilized by the Company based on the specific requirements of the HSS. Furthermore, although the Company initially explored the possibility of requesting a loan under the Small Business Administration Paycheck Protection Program, we elected not to complete an application because we are not certain we meet certain criteria of the program.second quarter.
INTERPACE BIOSCIENCES, INC

During April and early May 2020, the Company made payments totaling $888,000 to CGI for funds withheld from the Excess Consideration Note to satisfy certain adjustments and indemnification obligations under the Asset Purchase ~~Agreement.~~ Agreement dated July 15, 2019.
The ~~funds used~~Company has and may continue to ~~satisfy this obligation were not included~~delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The Company’s cash and cash equivalents ~~as of December 31, 2019~~balance is decreasing and March 31, 2020. These funds and the related liability were included in Other Assets and Other Current Liabilities, respectively, as of those period ends, and the settlement of the liability had no net impact on the Company’s operating cash flow or liquidity.
~~We do~~we will not ~~expect to~~ generate positive cash flows from operations for the year ending December 31, 2020. We intend to meet our ongoing capital needs by using our available cash, ~~proceeds under~~including the ~~Securities Purchase~~Ampersand and ~~Exchange Agreement, additional borrowings under the Line of Credit~~1315 Capital loans, as well as increasing our line of credit limit as a result of the additional accounts receivable acquired in July 2019 as part of our acquisition of pharma services (which requires a modification to the bank agreement and approval by SVB which cannot be assured, revenue growth and margin ~~improvement, collecting~~improvement; collection of accounts ~~receivable, containing costs as well as exploring~~receivable; containment of costs; and the potential use of other financing options. Our planned capital expenditures over the next twelve months currently includes several million dollars to be utilized in consolidating our laboratories, which includes equipment purchases, calibration and testing costs, moving and other related costs, and leasehold improvements. Management believes that the Company has sufficient cash on hand and available to sustain operations through at least June 30, 2021. However, in
In the event the ~~Company~~Company’s Common Stock is ~~unable to maintain its~~delisted from Nasdaq ~~listing for its common stock~~ due to aits failure to meet minimum ~~stockholder~~stockholders’ equity requirements, ~~as a result of the classification of its preferred stock as temporary equity and the amortization and impairment of certain intangible assets,~~ the Company’s ability to raise additional capital may be materially adversely impacted. ~~Therefore, there~~In addition, the Company’s inability to use Form S-3 after it files its Form 10-K for the fiscal year ended December 31, 2020 may have an adverse impact on our ability to raise additional capital. There is no ~~guarantee that additional~~assurance we will be successful in meeting our capital ~~can be raised~~requirements prior to ~~fund our future operations.~~becoming cash flow positive.
INTERPACE BIOSCIENCES, INC
Inflation

We do not believe that inflation had a significant impact on our results of operations for the periods presented. On an ongoing basis, we attempt to minimize any effects of inflation on our operating results by controlling operating costs and whenever possible, seeking to ~~insure~~ensure that billing rates reflect increases in costs due to inflation.

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of ~~disclosure controls~~Disclosure Controls and ~~procedures~~Procedures

~~As of the end of the period covered by this report, the Company’s~~Our management, with the participation of ~~the~~our Chief Executive Officer ~~(“CEO”)~~ and Chief Financial Officer, ~~(“CFO”), carried out an evaluation of~~evaluated the effectiveness of ~~the Company’s~~our disclosure controls and procedures ~~(as defined in Rules 13a-15(e) and 15d-15(e) of~~pursuant to Rule 13a-15 under the Exchange ~~Act). Based upon that evaluation, the then CEO and CFO concluded at that time that the Company’s disclosure controls and procedures were effective~~Act as of the end of the period covered by this ~~report.~~Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives including that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.

~~Subsequent to this~~Based on the evaluation ~~and in light~~ of the restatement of the Company’s condensed financial statements for the quarters ended March 31, 2020 and 2019 relating to the amortization and the impairment of certain intangible assets referenced in Note 1, Restatement of Previously Issued Consolidated Financial Statements, the Company’s management, with the participation of the CEO and the CFO, has reevaluated the Company’s disclosure controls and procedures, as that term is defined in Rule 13a-15(e) under the Exchange Act the Chief Executive Officer of ~~March 31, 2020, including whether~~ the ~~errors identified were~~Company and the ~~result~~Chief Financial Officer of ~~a material weakness in~~ the Company’s internal control over financial reporting. Based on this assessment, management has identified a material weakness in the Company’s internal control over financial reporting related to properly identifying all the events that could trigger an asset impairment. The Company did not properly amend policies and procedures associated with its valuation process for asset impairment, specifically for intangible assets, and as a result failed to develop appropriate control activities to adequately respond to the triggering events identified. As a result, the CEO and CFOhave concluded that the Company’s disclosure controls and procedures were not effective ~~March 31, 2020~~ as ~~a result~~ of ~~this material weakness.~~
Remediation Plan - The Company plans to amend its control activities designed to mitigate the significant risks identified, including updating its policies and procedures regarding the recognition of asset impairments, specifically to review the procedures identifying and considering all outside triggering events that can cause such impairments. The Company believes implementation of these processes and appropriate testing of their effectiveness will remediate this material weakness.September 30, 2020.

Reference should be made to our Form ~~10-K~~10-K/A filed with the SEC on January 19, 2021 for additional information regarding discussion of the effectiveness of the Company’s controls and procedures.

Changes in ~~internal controls~~Internal Controls

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
INTERPACE BIOSCIENCES, INC

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

~~None.~~We are currently a party to legal proceedings that are incidental to our business. While management currently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our business, financial condition, results of operations or cash flow, litigation is subject to inherent uncertainties. Were we to settle a proceeding for a material amount or were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our business, financial condition, results of operations or cash flows.
Item 1A. Risk Factors

Not applicable as we are a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

~~As disclosed in Item 8.01 of the May 15~~^th 8-K and in the Company’s definitive proxy statement, as filed with the SEC on June 10, 2020 (the “Proxy Statement”), the Company plans to hold its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) on July 9, 2020 at 10:00 a.m., Eastern Time. The 2020 Annual Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. Additional details regarding the location via the Internet and matters to be voted on at the 2020 Annual Meeting are available in the Proxy Statement.
None.
The Company’s 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”) was held on October 10, 2019. Because the date of the 2020 Annual Meeting represents a change of more than 30 days from the anniversary date of the 2019 Annual Meeting, the Company disclosed in the May 15^th 8-K a new deadline for the submission of stockholder proposals. In accordance with Rule 14a-5(f) of the Exchange Act and consistent with the Amended and Restated ByLaws of the Company, effective November 12, 2019, the Company informed stockholders that a proposal or notice on Schedule 14N under Rule 14a-18 under the Exchange Act (i) intended to be included in the Proxy Statement under Rule 14a-8 under the Exchange Act or (ii) intended to be presented at the 2020 Annual Meeting other than by inclusion in the Proxy Statement, must have been received by the Company on or prior to 5:00 p.m. Eastern Time on ~~May 28, 2020 to be considered timely. Any proposal or nomination received after such date will be considered untimely.~~INTERPACE BIOSCIENCES, INC
Item 6. Exhibits

Exhibit No. Description

3.1**10.1 ~~Conformed version of Certificate of Incorporation of~~Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace ~~Biosciences,~~Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma Solutions, Inc.~~, as amended by the Certificate of Amendment, effective January 15, 2020,~~ and ~~the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020,~~Silicon Valley Bank, incorporated by reference to Exhibit ~~3.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020.~~
~~10.1~~ Securities Purchase and Exchange Agreement, dated January 10, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.14.3 of the Company’s Current Report on Form 8-K, filed with the SEC on ~~January 14,~~October 23, 2020.
~~10.2~~ Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.
~~10.3~~ Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.
~~10.4#~~ Employment Agreement, dated as of January 29, 2020, by and between Interpace Biosciences, Inc. and Fred Knechtel, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.
~~10.5#~~ Severance and Consulting Agreement and General Release, dated January 29, 2020, by and between Interpace Biosciences, Inc. and James Early, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.
~~10.6#~~ First Amendment to Amended and Restated Employment Agreement, dated January 29, 2020, by and between Interpace Biosciences, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.
~~10.7~~ Eleventh Amendment to Lease, effective as of June 1, 2020, by and between Southport Business Park Limited Partnership and Interpace Pharma Solutions, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 9, 2020.
~~10.8*#~~ ~~Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, filed herewith.~~
~~10.9*#~~ ~~Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, filed herewith.~~

31.1* Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2* Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1+ Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

32.2+ Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.
101 The following financial information from this Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Stockholders’ Equity; (iv) the Condensed Consolidated Statements of Cash Flows; and (v) the Notes to Condensed Consolidated Financial Statements.
* Filed herewith.

+ Exhibits 32.1 and 32.2 are being furnished herewith and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference to any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

** This exhibit is being filed pursuant to Item 601(b)(3)(i) of Regulation S-K which requires a conformed version of the Company’s charter reflecting all amendments in one document. The exhibit reflects the Company’s Certificate of Incorporation, as amended, as amended by the Certificate of Amendment, effective January 15, 2020, and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020.
# ~~Denotes compensatory plan, compensation arrangement or management contract.~~Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 19, 2021
Interpace Biosciences, Inc.
(Registrant)

/s/ Thomas W. Burnell

Thomas W. Burnell
President and Chief Executive Officer
(Principal Executive Officer)

Date: January 19, 2021
/s/ Fred Knechtel
Fred Knechtel
Chief Financial Officer
(Principal Financial Officer)

Date: January 19, 2021
/s/ Thomas Freeburg
Thomas Freeburg
Chief Accounting Officer
(Principal Accounting Officer)

4643

	As Restated					As Restated
	For The Three Months Ended					For The Three Months Ended
	March 31, 2020					March 31, 2019
	Shares		Amount			Shares		Amount
Common stock:
Balance at January 1		3,932	$	393			2,877	$	287
Common stock issued		37		1			9		1
Restricted stock issued		6		-			-		-
Common stock issued through market sales		80		8			-		-
Common stock issued through offerings		-		-			933		94
Balance at March 31		4,055		402			3,819		382
Treasury stock:
Balance at January 1		12		(1,721	)		7		(1,680	)
Treasury stock purchased		-		-			3		(32	)
Balance at March 31		12		(1,721	)		10		(1,712	)
Additional paid-in capital:
Balance at January 1				182,514					175,820
Common stock issued through offerings, net of expenses				-					5,868
Extinguishment of Series A Shares				(828	)				-
Beneficial Conversion Feature in connection with Series B Issuance				2,205					-
Amortization of Beneficial Conversion Feature				(2,205	)				-
Common stock issued through market sales				476					-
Stock-based compensation expense				418					266
Balance at March 31				182,580					181,954
Accumulated deficit:
Balance at January 1				(185,665	)				(158,981	)
Net loss				(6,494	)				(3,326	)
Adoption of ASC 842				-					55
Balance at March 31				(192,159	)				(162,252	)

Total stockholders’ equity			$	(10,898	)			$	18,372

	For The Nine Months Ended					For The Nine Months Ended
	September 30, 2020					September 30, 2019
	Shares		Amount			Shares		Amount
Common stock:
Balance at January 1		3,932	$	393			2,877	$	287
Common stock issued		37		1			9		1
Restricted stock issued		6		-			-		-
Common stock issued through market sales		80		8			-		-
Common stock issued through offerings		-		-			933		94
Balance at March 31		4,055		402			3,819		382
Common stock issued		-		-			10		1
Balance at June 30		4,055		402			3,829		383
Common stock issued		5		-			-		-
Balance at September 30		4,060		402			3,829		383
Treasury stock:
Balance at January 1		12		(1,721	)		7		(1,680	)
Treasury stock purchased		-		-			3		(32	)
Balance at March 31		12		(1,721	)		10		(1,712	)
Treasury stock purchased		7		(49	)		-		-
Balance at June 30		19		(1,770	)		10		(1,712	)
Treasury stock purchased		-		-			-		-
Balance at September 30		19		(1,770	)		10		(1,712	)
Additional paid-in capital:
Balance at January 1				182,514					175,820
Common stock issued through offerings, net of expenses				-					5,868
Extinguishment of Series A Shares				(828	)				-
Beneficial Conversion Feature in connection with Series B Issuance				2,205					-
Amortization of Beneficial Conversion Feature				(2,205	)				-
Common stock issued through market sales				476					-
Stock-based compensation expense				418					266
Balance at March 31				182,580					181,954
Common Stock issued				-					72
Stock-based compensation expense				400					205
Balance at June 30				182,980					182,231
Dividends accrued				-					(75	)
Stock-based compensation expense				563					205
Balance at September 30				183,543					182,361
Accumulated deficit:
Balance at January 1				(185,665	)				(158,981	)
Net loss				(6,494	)				(3,326	)
Adoption of ASC 842				-					55
Balance at March 31				(192,159	)				(162,252	)
Net loss				(5,580	)				(5,304	)
Balance at June 30				(197,739	)				(167,556	)
Net loss				(6,234	)				(7,446	)
Balance at September 30				(203,973	)				(175,002	)

Total stockholders’ equity			$	(21,798	)			$	6,030

	As Restated
	For The Three Months Ended March 31,						For The Nine Months Ended September 30,
	2020			2019			2020			2019

Cash Flows From Operating Activities
Net loss	$	(6,494	)	$	(3,326	)	$	(18,308	)	$	(16,077	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,319			957			4,102			3,164
Interest accretion		109			129			414			331
Reversal of 2019 bonus accrual								(1,156	)		-
Mark to market on warrants		(26	)		(3	)		(62	)		(35	)
Stock-based compensation		418			538			1,381			1,246
Bad debt expense		250			-			250			499
Other gains and expenses, net		-			18			-			18
Other changes in operating assets and liabilities:
Decrease (increase) in accounts receivable		289			(1,738	)		1,625			(1,986	)
(Increase) decrease in other current assets		(1,125	)		11
(Decrease) increase in accounts payable		(253	)		93
(Decrease) increase in accrued salaries and bonus		(476	)		205
(Decrease) increase in accrued liabilities		(1,149	)		99
Increase in long-term liabilities		16			57
Increase in other current assets								(898	)		(417	)
Increase in long-term assets								-			(11	)
Decrease in accounts payable								(1,319	)		(766	)
Increase in accrued salaries and bonus								129			108
Increase in accrued liabilities								1,472			924
(Decrease) increase in long-term liabilities								(25	)		446
Net cash used in operating activities		(7,122	)		(2,960	)		(12,395	)		(12,556	)

Cash Flows From Investing Activity
Acquisition of Biopharma, net of expenses								-			(13,829	)
Purchase of property and equipment		-			(12	)		(1,275	)		(105	)
Sale of property and equipment		-			13			-			13
Net cash provided by investing activity		-			1
Net cash used in investing activities								(1,275	)		(13,921	)

Cash Flows From Financing Activities
Issuance of common stock, net of expenses		434			6,015			434			5,962
Payments on Line of Credit		(1,800	)		-
Issuance of preferred shares, net of expenses								-			13,087
(Payments) borrowings on Line of Credit, net								(3,000	)		3,750
Issuance of Series B preferred stock, net of expenses		19,537			-			19,223			-
Cash paid for repurchase of restricted shares								-			(32	)
Net cash provided by financing activities		18,171			6,015			16,657			22,767

Net increase in cash and cash equivalents		11,049			3,056
Net increase (decrease) in cash and cash equivalents								2,987			(3,710	)
Cash and cash equivalents – beginning		2,321			6,068			2,321			6,068
Cash and cash equivalents – ending	$	13,370		$	9,124		$	5,308		$	2,358

	a)	Amortization expense - We recorded amortization expense starting at the dates of acquisition for our Barrett’s and Thyroid intangible assets. The impact of the additional amortization charge was approximately $0.1 million in the quarters ended March 31, 2020 and March 31, 2019, respectively.

	b)	~~Asset impairment - We recorded an impairment charge on our Barrett’s intangible asset of approximately $11.6 million in the fourth quarter of 2016.~~

	c)	~~Adjustments - Adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years’ financial statements.~~

	March 31, 2020
	As Previously Reported			Restatement Amount			Restatement Reference		As Restated
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	13,370		$	-				$	13,370
Accounts receivable, net of allowance for doubtful accounts of $275		9,799			-					9,799
Other current assets		4,976			-					4,976
Total current assets		28,145			-					28,145
Property and equipment, net		6,610								6,610
Other intangible assets, net		32,470			(17,736	)		(a) (b)		14,734
Goodwill		8,433			-					8,433
Operating lease right of use assets		2,811			-					2,811
Other long-term assets		42			-					42
Total assets	$	78,511		$	(17,736	)			$	60,775

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	4,456		$	-				$	4,456
Accrued salary and bonus		1,865			-					1,865
Other accrued expenses		8,639			-					8,639
Current liabilities from discontinued operations		766			-					766
Total current liabilities		15,726			-					15,726
Contingent consideration		2,264			-					2,264
Operating lease liabilities, net of current portion		1,384			-					1,384
Line of credit		1,200			-					1,200
Other long-term liabilities		4,563			-					4,563
Total liabilities		25,137			-					25,137

Commitments and contingencies (Note 8)

Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B shares issued and outstanding		46,536			-					46,536

Stockholders’ equity:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,055,454 and 4,043,673 shares issued and outstanding, respectively;		402			-					402
Additional paid-in capital		182,580			-					182,580
Accumulated deficit		(174,423	)		(17,736	)		(a) (b) (c)		(192,159	)
Treasury stock, at cost (11,781 shares)		(1,721	)		-					(1,721	)
Total stockholders’ equity		6,838			(17,736	)				(10,898	)
Total liabilities and stockholders’ equity	$	31,975		$	(17,736	)			$	14,239

Total liabilities, preferred stock and stockholders’ equity	$	78,511		$	(17,736	)			$	60,775

	Three Months Ended March 31, 2020										Three Months Ended March 31, 2019
	As Previously Reported			Restatement Amount			Restatement Reference	As Restated			As Previously Reported			Restatement Amount			Restatement Reference	As Restated

Revenue, net	$	9,200		$	(141	)	(c)	$	9,059		$	6,010		$	-			$	6,010
Cost of revenue		6,113			-				6,113			2,622			-				2,622
Gross profit		3,087			(141	)	(c)		2,946			3,388			-				3,388
Operating expenses:
Sales and marketing		2,481			-				2,481			2,411			-				2,411
Research and development		809			-				809			528			-				528
General and administrative		4,887			6		(c)		4,893			2,912			(177	)	(c)		2,735
Acquisition related amortization expense		1,031			84		(a)		1,115			813			84		(a)		897
Total operating expenses		9,208			90		(a) (c)		9,298			6,664			(93	)	(a) (c)		6,571

Operating loss		(6,121	)		(231	)	(a) (c)		(6,352	)		(3,276	)		93		(a) (c)		(3,183	)
Interest accretion		(109	)		-				(109	)		(129	)		-				(129	)
Other income (expense), net		47			-				47			48			-				48
Loss from continuing operations before tax		(6,183	)		(231	)	(a) (c)		(6,414	)		(3,357	)		93		(a) (c)		(3,264	)
Provision for income taxes		15			-				15			5			-				5
Loss from continuing operations, net of tax		(6,198	)		(231	)	(a) (c)		(6,429	)		(3,362	)		93		(a) (c)		(3,269	)

Loss from discontinued operations, net of tax		(65	)		-				(65	)		(57	)		-				(57	)

Net loss		(6,263	)		(231	)	(a) (c)		(6,494	)		(3,419	)		93		(a) (c)		(3,326	)

Less adjustment for preferred stock deemed dividend		(3,033	)		-				(3,033	)		-			-				-

Net loss attributable to common stockholders		(9,296	)		(231	)			(9,527	)		(3,419	)		93				(3,326	)

Basic and diluted loss per share of common stock:
From continuing operations	$	(2.31	)	$	(0.06	)		$	(2.37	)	$	(0.96	)	$	0.03			$	(0.93	)
From discontinued operations		(0.01	)		-				(0.01	)		(0.01	)		-				(0.01	)
Net loss per basic and diluted share of common stock	$	(2.32	)	$	(0.06	)		$	(2.38	)	$	(0.97	)	$	0.03			$	(0.94	)
Weighted average number of common shares and common share equivalents outstanding:
Basic		4,004			4,004				4,004			3,515			3,515				3,515
Diluted		4,004			4,004				4,004			3,515			3,515				3,515

	September 30, 2020		December 31, 2019
	(unaudited)
Lab supply inventory		2,423		1,825
Prepaid expenses		489		971
Funds in escrow		-		888
Letter of credit		350		-
Due from CGI		525		92
Other		74		75
Total other current assets	$	3,861	$	3,851

			As Restated			As Restated
			As of March 31, 2020			As of December 31, 2019					As of September 30, 2020			As of December 31, 2019
	Life		Carrying			Carrying			Life		Carrying			Carrying
	(Years)		Amount			Amount			(Years)		Amount			Amount

Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519			9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141			7		16,141			16,141
Barrett’s test		9		6,719			6,719			9		6,719			6,719
BioPharma acquisition:
Trademarks		10		1,600			1,600			10		1,600			1,600
Customer relationships		8		5,700			5,700			8		5,700			5,700

CLIA Lab		2.3	$	609		$	609			2.3	$	609		$	609

Total			$	39,288		$	39,288				$	39,288		$	39,288

Accumulated Amortization			$	(24,554	)	$	(23,439	)			$	(26,784	)	$	(23,439	)

Net Carrying Value			$	14,734		$	15,849				$	12,504		$	15,849

	Carrying
	Amount
Balance as of December 31, 2019	$	8,433
Adjustments		-
Balance as of March 31, 2020	$	8,433

	Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

	Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

											As of September 30, 2020				Fair Value Measurements
	As of March 31, 2020				Fair Value Measurements						Carrying		Fair		As of September 30, 2020
	Carrying		Fair		As of March 31, 2020						Amount		Value		Level 1		Level 2		Level 3
	Amount		Value		Level 1		Level 2		Level 3						(unaudited)
Liabilities:						(unaudited)
Contingent consideration:
Asuragen ⁽¹⁾	$	2,866	$	2,866	$	-	$	-	$	2,866	$	2,806	$	2,806	$	-	$	-	$	2,806
Other long-term liabilities:
Warrant liability ⁽²⁾		55		55		-		-		55		20		20		-		-		20
	$	2,921	$	2,921	$	-	$	-	$	2,921	$	2,826	$	2,826	$	-	$	-	$	2,826

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2019		Payments			Accretion		Conversions Exercises		Mark to Market			March 31, 2020
	(unaudited)
Asuragen	$	2,893	$	(136	)	$	109	$	-	$	-		$	2,866

Underwriters Warrants		82		-			-		-		(27	)		55
	$	2,975	$	(136	)	$	109	$	-	$	(27	)	$	2,921

								Cancellation of Obligation/		Adjustment to Fair Value/
	December 31, 2019		Payments			Accretion		Conversions Exercises		Mark to Market			September 30, 2020
						(unaudited)
Asuragen	$	2,893	$	(501	)	$	414	$	-	$	-		$	2,806

Underwriters Warrants		82		-			-		-		(62	)		20
	$	2,975	$	(501	)	$	414	$	-	$	(62	)	$	2,826

	Classification on the Balance Sheet	March 31, 2020		Classification on the Balance Sheet	September 30, 2020
		(unaudited)			(unaudited)
Assets
Financing lease assets	Property and equipment, net	$	475	Property and equipment, net	$	470
Operating lease assets	Operating lease right of use assets		2,811	Operating lease right of use assets		4,758
Total lease assets		$	3,286		$	5,228

Liabilities
Current
Financing lease liabilities	Other accrued expenses	$	160	Other accrued expenses	$	134
Operating lease liabilities	Other accrued expenses		1,251	Other accrued expenses		1,110
Total current lease liabilities		$	1,411		$	1,244
Noncurrent
Financing lease liabilities	Other long-term liabilities		85	Other long-term liabilities		33
Operating lease liabilities	Operating lease liabilities, net of current portion		1,384	Operating lease liabilities, net of current portion		3,746
Total long-term lease liabilities			1,469			3,779
Total lease liabilities		$	2,880		$	5,023

	Operating Leases		Financing Leases		Operating Leases		Financing Leases
2020		1,189		170		365		49
2021		878		120		1,235		120
2022		660		13		1,028		13
2023		250		-		629		-
2024-2030						2,717
Total minimum lease payments		2,977		303		5,974		182
Less: amount of lease payments representing effects of discounting		342		58		1,118		13
Present value of future minimum lease payments		2,635		245		4,856		169
Less: current obligations under leases		1,251		160		1,110		134
Long-term lease obligations	$	1,384	$	85	$	3,746	$	35

			Less than		1 to 3		3 to 5		After
	Total		1 Year		Years		Years		5 Years
Operating lease obligations	$	2,977	$	1,189	$	1,538	$	250	$	-

Description	Classification	Exercise Price		Expiration Date	Warrants Issued		Warrants Exercised			Warrants Cancelled/ Expired			Balance December 31, 2019		Balance March 31, 2020

Private Placement Warrants, issued January 25, 2017	Equity	$	46.90	June 2022		85,500		-			-			85,500		85,500
RedPath Warrants, issued March 22, 2017	Equity	$	46.90	September 2022		10,000		-			-			10,000		10,000
Underwriters Warrants, issued June 21, 2017	Liability	$	13.20	December 2022		57,500		-			(4,000	)		53,500		53,500
Base & Overallotment Warrants, issued June 21, 2017	Equity	$	12.50	June 2022		1,437,500		(567,286	)		-			870,214		870,214
Vendor Warrants, issued August 6, 2017	Equity	$	12.50	August 2020		15,000		-			-			15,000		15,000
Warrants issued October 12, 2017	Equity	$	18.00	April 2022		320,000		-			-			320,000		320,000
Underwriters Warrants, issued January 25, 2019	Equity	$	9.40	January 2022		65,434		-			-			65,434		65,434

						1,990,934		(567,286	)		(4,000	)		1,419,648		1,419,648

	●	material adverse impact of Coronavirus (COVID-19) pandemic due to the slowdown in demand for our clinical services and pharma services, a reduction in samples received and testing volume and delayed third party collections and other factors;

	●	~~we have~~the substantial doubt about our ability to continue as a going concern due to our history of operating losses, declining cash position and other liquidity factors, which in the absence of additional short term financing may cause us to cease or scale back operations;

	●	the limited revenue generated by our clinical services and pharma ~~services have generated limited revenue;~~services;

	●	we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability;

	●	our limited operating history, ~~and~~ the limited revenue generated from our business thus far and our fluctuating quarterly and annual revenue and operating results, including as a result of how we recognize revenue;

	●	our ability to timely file our SEC reports the failure of which could result in a delisting from Nasdaq, and loss of eligibility for certain registration statements and exemptions for resales;

	●	the failure to meet Nasdaq minimum stockholders’ equity requirement as of June 30, 2020 resulting in a letter from Nasdaq notifying us of the failure to meet this listing requirement and commencing procedures to potentially delist our Common Stock from Nasdaq, as well as the increased difficulty in meeting the minimum stockholders’ equity requirement as a result of the impairment charge, which delisting (if effected) could lead to a possible reduced stock price, potentially causing difficulty raising additional capital or debt, and also resulting in the loss of exemptions from various state securities laws;

	●	we generally depend on sales and reimbursements from our clinical services for more than 50% of our ~~revenue, and we will need~~revenue; the ability to continue to generate sufficient revenue from these and other products and/or solutions that we develop ~~or require~~in the future is important for our ability to ~~grow~~meet our ~~business;~~financial and other targets;

	●	we rely on third parties to process and transmit claims to payers for our clinical services, and any delay, data loss, or other disruption in processing or transmitting could have an adverse effect on our revenue and financial condition;

	●	our ability to utilize our commercial and operating experience to sell our clinical and pharma services;

	●	our ability to compete successfully in the markets that our clinical services and pharma services operate in;

	●	our ability to obtain, retain and increase sufficient levels of ~~third party~~third-party reimbursement for our ~~molecular diagnostic~~clinical services tests in a changing and challenging reimbursement environment, including our current dependence on a concentrated number of third-party payers, ~~and~~ the lack of timeliness of their payments and the potential failure of such payments to ever occur;

	●	our billing practices and those of our third-party billing providers that can impact our ability to effectively bill and collect on claims for the sale of our clinical tests;

	●	our revenue recognition is based, in part, on our estimates for future collections and such estimates may prove to be incorrect;


	●	a deterioration in the collectability of our accounts receivable could have a material adverse effect on our business, financial condition and results of operations;

	●	~~our~~the inability to finance our business on acceptable terms in the future may limit ~~our~~the ability to grow our business, develop and commercialize products and services, develop and commercialize new molecular ~~diagnostic~~clinical service solutions and technologies and expand our pharma ~~services;~~

	●	our ability to comply with financial covenants under our current line of credit facility and comply with our debt obligations and our ability to expand our working capital borrowing base to provide sufficient working capital financing during growth periods;services offerings;

	●	we have issued convertible preferred stock, and may issue additional convertible preferred stock in the future, ~~and the~~that includes terms ~~of our preferred stock~~that may dilute our ~~common stock;~~Common Stock;

	●	the concentration of our ownership in two private equity firms and their affiliates that control, on an as-converted basis, 66% of our fully diluted outstanding shares of ~~common stock~~Common Stock through their holdings of Series B ~~Convertible~~ Preferred Stock, ~~par value $0.01 per share (“Series B Preferred Stock”), and this concentration of ownership along with having authority for~~as well as their corresponding designation rights for a majority of our directors ~~will have~~and their right to approve certain of our actions, has resulted in these stockholders having a substantial influence on our business decisions;

	●	as billing for our clinical services tests is complex, ~~and~~ we must dedicate substantial time and resources to its invoicing process and are continuously taking measures to improve the ~~billing process to be paid for~~success of our ~~clinical services;~~accounts receivable collection activities;

	●	we depend onupon a ~~few~~small number of payers for a significant portion of our ~~revenue for our~~ clinical services and ifcould experience a decline in revenue, as well as a compromise to our commercial success, should one or more ~~significant~~of these payers ~~stops providing~~stop, delay or decrease reimbursement ~~or decreases the amount of reimbursement for our tests, our revenue could decline;~~payments;

	●	if payers do not provide reimbursement, rescind or modify their reimbursement policies or delay payments for our clinical services, we could experience a decline in revenue and our commercial success could be compromised;

	●	~~developing~~the development of new tests, products and related services and solutions ~~includes~~typically requires a lengthy, complex and ~~complex~~costly process ~~with~~and development activities could prove unsuccessful or yield uncertain results;

	●	the effect of potential adverse findings, including potential laboratory shut downs, resulting from regulatory audits and inspections of our facilities, as well as our billing and payment practices, and the impact such ~~results~~adverse findings could have on our continuing business operations;

	●	a decline in demand for our clinical ~~services;~~services tests and/or our pharma services products;

	●	the ~~demand for~~failure of our ~~molecular diagnostic tests from physicians~~products and ~~patients;~~services to perform as forecast;

	●	~~our products and services continuing to perform as expected;~~

	●	customer claims against us ~~for~~asserting inaccurate results from our ~~molecular diagnostic tests;~~clinical services tests or our pharma services products;

	●	our obligations to make royalty and milestone payments to our licensors;

	●	our ability to obtain the data and samples that are needed to perform ~~sufficient~~the clinical studies that will enable us to ~~successfully~~ publish data demonstrating the clinical relevance and value of our ~~molecular diagnostic~~clinical services tests, including to support sufficient levels of ~~third party~~third-party reimbursement;

	●	our dependence on third parties for the supply of some of the materials used in our ~~molecular diagnostic tests~~clinical and pharma ~~services;~~services tests;

	●	our ability to successfully scale our operations, which could potentially result in delays in providing test results or ~~delays or reagent and supply~~in shortages for our tests and services;

	●	our ability to develop or acquire tests, services or solutions;


	●	the ability of our clinical services to enter into ~~additional clinical study~~ collaborations with highly regarded institutions;

	●	the ~~effect~~potential adverse impact of current and future laws, licensing requirements and ~~regulation have on~~governmental regulations upon our business operations, including but not limited to the ~~changing~~evolving U.S. ~~Food and Drug Administration~~regulatory environment ~~as it relates~~related to ~~molecular diagnostics and pharma services and~~ laboratory developed tests ~~(LDT’s);~~

	●	~~changes in governmental regulations mandating price controls~~(“LDTs”), pricing of our tests and ~~limitations on~~services and patient access ~~to our products and services;~~limitations;

	●	if we fail to comply with Federal, State and foreign laboratory licensing requirements, we could lose the ability to perform our tests ~~or experience~~resulting in disruptions to our business;

	●	legislation reforming the U.S. healthcare system;

	●	a failure to comply with Federal and State laws and regulations pertaining to our ~~payment practices;~~billing practices could result in our being excluded from participation in Medicare, Medicaid or other governmental payer programs and/or significant monetary fines;

	●	our ability to comply with U.S. fraud and abuse laws, oras well as payer regulations, could result in our being excluded from participation in Medicare, Medicaid or other governmental payer ~~programs;~~programs and/or significant monetary fines;

	●	compliance with numerous statutes and regulations pertaining to our business;

	●	the effect of The Eliminating Kickbacks in Recovery Act of 2018 asto the extent that it ~~potentially impacts~~could negatively impact our ability to incentivize our sales ~~personnel appropriately;~~personnel;

	●	our ability to realize all of the anticipated benefits of the acquisition of our pharma services or those benefits, if any, taking longer to realize than ~~expected;~~was forecasted;

	●	if pharmaceutical and biotech companies, universities and contract research organizations performing clinical trials decide not to use our tests and services, we may be unable to generate sufficient revenue to sustain our pharma services;

	●	if we fail to perform our pharma services in accordance with contractual and regulatory requirements, and ethical considerations, we could be subject to significant costs, ~~or liability;~~

	●	~~our ability to compete~~legal liabilities and could experience a decline in ~~the markets our clinical services operate in;~~revenue;

	●	our ability to attract and retain key employees and management personnel;

	●	our reliance on our sales and marketing ~~forces~~activities for future business growth and our ability to continue to expand our sales and marketing ~~forces;~~activities;

	●	our limited experience in marketing and selling our products;

	●	the ability of our clinical services tests to be successfully embraced by physicians and members of the medical community who have historically used traditional methods to diagnose gastrointestinal and endocrine cancers;

	●	~~the~~our ability ~~of our molecular diagnostic tests~~ to effectively compete ~~successfully with physicians and members of the medical community who use traditional methods to diagnose gastrointestinal and endocrine cancers,~~against competitors ~~offering broader~~that offer product lines ~~outside of~~that extend beyond the ~~molecular diagnostic~~clinical services testing market, ~~and having~~that have greater brand recognition ~~than we do,~~ and ~~companies with~~that possess greater financial resources;

	●	our ability to license rights to use emerging technologies ~~in order~~that will enhance our ability to commercialize new products and services;

	●	the potential for liabilities or restraints on our ~~involvement in~~business as a result of unanticipated, future litigation, ~~against us~~as well as our potential inability to enforce legal judgments or ~~our ability to~~ collect ~~on judgements found~~monetary damages awarded in our favor;

	●	the ~~effect~~adverse impact of force majeure events, including but not limited to acts of nature, ~~seasonal results and~~ adverse weather conditions, hurricanes and floods, onepidemics and pandemics upon our business and the ability of our ~~suppliers;~~suppliers to provide us with critical materials and services;


	●	our use of hazardous materials;

	●	the susceptibility of our information systems to security breaches, loss of data and other disruptions;

	●	catastrophic loss of our laboratories;

	●	our ability to obtain and maintain sufficient qualified laboratory space to meet ~~our~~the processing needs ~~for all~~ of our business, as well as our ability to pass regulatory inspections and continue to be Clinical Laboratory Improvement Amendments (“CLIA”) and the College of American Pathologists ~~(“CAP”)~~ certified or accredited;

	●	compliance with the U.S. Foreign Corrupt Practices Act and anti-bribery laws;

	●	our ability to respond to rapid scientific changes in the areas in which we operate;

	●	our compliance with our license agreements and our ability to protect and defend our intellectual property rights;

	●	patent infringement claims against us;

	●	changes in U.S. and global patent law;

	●	tax reform legislation;

	●	stock dilution;

	●	changes in financial accounting standards or practices;

	●	exposure to international law, regulations and risk as a result of international expansion;

	●	we may acquire businesses or assets or make investments in other companies or testing, service or solution technologies that could ~~harm our operating~~negatively impact the results of business operations, dilute our stockholders’ ownership, increase our debts and/or cause us to incur significant ~~expense;~~expenses;

	●	the potential impact of existing and future contingent liabilities on our financial condition;

	●	the results of any future impairment testing for intangible assets as required under U.S. generally accepted accounting principles (“GAAP”);

	●	our ability to remediate material weaknesses in internal controls and to maintain and implement effective internal controls over financial reporting, especially as we are consolidating operations;

	●	if our information technology or communications systems fail or we experience a significant interruption in their operation, our reputation, business and results of operations could be materially and adversely affected;

	●	the impact of future issuances of debt, common and preferred shares on stockholders’ interest and stock price;

	●	our ability to report financial results on a timely and accurate basis;

	●	our ability to manage our growth or unexpected declines;

	●	the potential that the temporary equity classification of our preferred stock and the amortization and impairment of certain intangible assets set forth herein may trigger a Nasdaq compliance default for failure to meet minimum stockholder equity requirements which could result in a delisting of our common stock from Nasdaq leading to a possible reduced stock price; potential difficulty in raising additional capital or debt as well as loss of exemptions from various state securities laws which could hamper action plans to remediate such a Nasdaq compliance default;

	●	uncertainty regarding the regulatory obligations related to our receipt of $650,000 funding for ~~COVID~~COVID-19 testing;

	●	~~our ability to rebuild our cost structure in anticipation of volume growth that does not happen as planned;~~

	●	the potential impact ~~on customers currently in~~of the relocation of our laboratory activities from Rutherford, NJ facility to our North Carolina facility upon ongoing customer clinical trials ~~in our Rutherford, NJ lab that we are now relocating~~if revalidation is delayed with respect to ~~North Carolina which may require revalidation in~~ the new site;

	●	the impact of ~~increased~~ costs ~~building expanded~~associated with expanding our laboratory capabilities in North Carolina in ~~anticipation~~connection with the relocation of ~~the move~~operations from Rutherford, NJ, ~~and~~as well as the potential for loss of customers ~~related to the move;~~as a result of this relocation;

	●	our ability to efficiently execute and complete the planned laboratory ~~move~~transition from Rutherford, NJ to North Carolina on a timely basis and within our forecasted costs;

	●	~~the risk of~~potential loss of personnel that are uniquely qualified to perform the breadth of specialty testing and lab applications necessary for developing customized assays in our pharma ~~solutions business;~~services;

	●	potential legal liabilities related to our employees, contractors and other third parties asserting claims for damages arising from workplace exposure to certain infectious agents, including but not limited to the COVID-19 virus;

	●	the possibility that we may have to cease laboratory operations at one or more facilities for an undefined period of time due to the contraction of COVID-19 by persons that have been in such facilities, resulting in our inability to satisfy contractual obligations, a loss of revenue and other potential legal liabilities;

	●	certain payors may decline to reimburse us for services rendered and billed using new billing codes currently in use with Medicare;

	●	the inability to charge and collect payment for the Company’s serology antibody ELISA test for COVID-19 or the inability to coordinate the technology with a polymerase chain reaction test;

	●	the inability to raise capital in the future under the terms of our preferred stock arrangement could result in a Nasdaq market delisting and possibly in the Company seeking creditor protection pursuant to U.S. bankruptcy laws;

	●	the inability by the Company to consolidate its multiple LIM’s programs into one functioning LIM’s program in the North Carolina laboratory could negatively impact the operations of our pharma services;

	●	the risk of a breach of proprietary or confidential data, regulated data, and personal information of employees, customers and others; successful breaches, employee malfeasance, or human or technological error that could result in, unauthorized access to, disclosure, modification, misuse, loss, or destruction of company, customer, or other third party data or systems; theft of sensitive, regulated, or confidential data including personal information and intellectual property; the loss of access to critical data or systems through ransomware, destructive attacks or other means; and business delays, service or system disruptions or denials of service, as well as legal consequences under Federal, state and other applicable laws and regulations;

	●	the risk and cost associated with whistleblower threats, interventions and lawsuits on our business and the cost of responding to such matters;

	●	our ability to respond to rapid scientific change;

	●	the risk of liability in conducting clinical trials and the sufficiency of our insurance to cover such claims;

	●	our ability to implement our business strategy;

	●	Food and Drug Administration (“FDA”) regulation of LDTs;

	●	our ability to integrate future acquisitions and costs related to such acquisitions;

	●	our ability to hire and retain sufficient managerial, sales, ~~reps fully reengaging with customers after reducing physical visits by~~clinical and other personnel to meet our ~~commercial team during the pandemic.~~needs; and

	●	our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure.

●	In February 2020, we announced an increase in Medicare reimbursement for our ThyraMIR^® test from $1,800 to $3,000, retroactive to January 1, 2020, reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices.

●	In March 2020, we announced ~~we had entered into a contract~~an agreement with Blue Cross Blue Shield of Massachusetts ~~making~~under which ThyGeNEXT^®and ThyraMIR^® tests are now covered in-network services for their more than 3 million members in Massachusetts and across New England.


●	In March 2020, we announced ~~we had entered into a contract~~an agreement with CareFirst Blue Cross Blue Shield ~~making ThyGeNEXT®~~that makes ThyGeNEXT^® and ~~ThyraMIR®~~ ThyraMIR^®tests covered in-network services for their more than 3.3 million members in Maryland, Washington, D.C., and Northern Virginia.

●	In March 2020, we announced we had entered into a contract with Premera Blue Cross, making ~~ThyGeNEXT®~~ThyGeNEXT^® and ~~ThyraMIR®~~ ThyraMIR^®tests covered in-network services for their more than 2 million members in Washington State and Alaska.

●	In April 2020, we executed an agreement with Avalon Healthcare Solutions (Avalon), a laboratory benefit manager representing numerous health plans. ~~Our~~This agreement ~~with Avalon offers us~~provides in-network status for our products to approximately 5.8 million lives covered by the following health plans: Blue Cross Blue Shield North Carolina, South Carolina, Kansas City and Vermont, and Capital Blue Cross of Central Pennsylvania.

●	In April 2020, we executed a contract with Blue Cross of Idaho making ~~ThyGeNEXT®~~ThyGeNEXT^® and ~~ThyraMIR®~~ThyraMIR^® tests covered in-network services for their more than ~~576 thousand~~576,000 members.

●	In May 2020, we executed a contract with Blue Cross Blue Shield of Wyoming.

●	In July 2020, we announced that our peer reviewed manuscript, describing results from a seminal clinical validation study of the combination of ThyGeNEXT^® and ThyraMIR^®, was accepted for publication in the highly respected journal Diagnostic Cytopathology and also accepted as a podium presentation for the American Society of Cytopathology (ASC) Annual Meeting. On August 7, 2020 this publication was made available on-line.

●	In December 2020, we executed an agreement with Regence Blue Cross Blue Shield of Washington State, Utah, Oregon, and Idaho.

●	In December 2020, we executed an agreement with HealthNow New York, parent company of Blue Cross Blue Shield of Western New York, and Blue Cross Blue Shield of Northeastern New York.

●	In December, 2020, we executed an agreement with Florida Blue/Blue Cross Blue Shield of Florida, which was effective January 1, 2021.

●	In December 2020, Medicare increased pricing for our ThyGeNEXT^® test from $600 to $2,900. We began realizing reimbursement at the higher rate starting in January 2021.

	As Restated
	Three Months Ended March 31,												Three Months Ended September 30,
	2020			2020			2019			2019			2020			2020			2019			2019

Revenue, net	$	9,059			100.0	%	$	6,010			100.0	%	$	8,248			100.0	%	$	7,725			100.0	%
Cost of revenue		6,113			67.5	%		2,622			43.6	%		5,194			63.0	%		4,835			62.6	%
Gross profit		2,946			32.5	%		3,388			56.4	%		3,054			37.0	%		2,890			37.4	%
Operating expenses:
Sales and marketing		2,481			27.4	%		2,411			40.1	%		2,699			32.7	%		2,757			35.7	%
Research and development		809			8.9	%		528			8.8	%		763			9.3	%		857			11.1	%
General and administrative		4,893			54.0	%		2,735			45.5	%		4,482			54.3	%		4,492			58.1	%
Acquisition related amortization expense		1,115			12.3	%		897			14.9	%
Acquisition related expense														-			0.0	%		838			10.8	%
Acquisition amortization expense														1,115			13.5	%		1,079			14.0	%
Total operating expenses		9,298			102.6	%		6,571			109.3	%		9,059			109.8	%		10,023			129.7	%

Operating loss		(6,352	)		-70.1	%		(3,183	)		-53.0	%		(6,005	)		-72.8	%		(7,133	)		-92.3	%
Interest accretion		(109	)		-1.2	%		(129	)		-2.1	%		(138	)		-1.7	%		(111	)		-1.4	%
Other income (expense), net		47			0.5	%		48			0.8	%		(12	)		-0.1	%		(135	)		-1.7	%
Loss from continuing operations before tax		(6,414	)		-70.8	%		(3,264	)		-54.3	%		(6,155	)		-74.6	%		(7,379	)		-95.5	%
Provision for income taxes		15			0.2	%		5			0.1	%		14			0.2	%		9			0.1	%
Loss from continuing operations		(6,429	)		-71.0	%		(3,269	)		-54.4	%		(6,169	)		-74.8	%		(7,388	)		-95.6	%

Loss from discontinued operations, net of tax		(65	)		-0.7	%		(57	)		-0.9	%		(65	)		-0.8	%		(58	)		-0.8	%

Net loss	$	(6,494	)		-71.7	%	$	(3,326	)		-55.3	%	$	(6,234	)		-75.6	%	$	(7,446	)		-96.4	%

	Nine Months Ended September 30,
	2020			2020			2019			2019

Revenue, net	$	22,752			100.0	%	$	20,005			100.0	%
Cost of revenue		15,156			66.6	%		10,489			52.4	%
Gross profit		7,596			33.4	%		9,516			47.6	%
Operating expenses:
Sales and marketing		6,776			29.8	%		8,127			40.6	%
Research and development		2,123			9.3	%		2,032			10.2	%
General and administrative		13,481			59.3	%		9,613			48.1	%
Acquisition related expense		-			0.0	%		2,534			12.7	%
Acquisition amortization expense		3,346			14.7	%		2,874			14.4	%
Total operating expenses		25,726			113.1	%		25,180			125.9	%

Operating loss		(18,130	)		-79.7	%		(15,664	)		-78.3	%
Interest accretion		(414	)		-1.8	%		(331	)		-1.7	%
Other (expense) income, net		473			2.1	%		(12	)		-0.1	%
Loss from continuing operations before tax		(18,071	)		-79.4	%		(16,007	)		-80.0	%
Provision for income taxes		43			0.2	%		19			0.1	%
Loss from continuing operations		(18,114	)		-79.6	%		(16,026	)		-80.1	%

Loss from discontinued operations, net of tax		(194	)		-0.9	%		(51	)		-0.3	%

Net loss	$	(18,308	)		-80.5	%	$	(16,077	)		-80.4	%

Exhibit No.		Description

3.1**10.1		~~Conformed version of Certificate of Incorporation of~~Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace ~~Biosciences,~~Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma Solutions, Inc.~~, as amended by the Certificate of Amendment, effective January 15, 2020,~~ and ~~the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020,~~Silicon Valley Bank, incorporated by reference to Exhibit ~~3.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020.~~

~~10.1~~		Securities Purchase and Exchange Agreement, dated January 10, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.14.3 of the Company’s Current Report on Form 8-K, filed with the SEC on ~~January 14,~~October 23, 2020.

~~10.2~~		Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.

~~10.3~~		Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020.

~~10.4#~~		Employment Agreement, dated as of January 29, 2020, by and between Interpace Biosciences, Inc. and Fred Knechtel, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.

~~10.5#~~		Severance and Consulting Agreement and General Release, dated January 29, 2020, by and between Interpace Biosciences, Inc. and James Early, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.

~~10.6#~~		First Amendment to Amended and Restated Employment Agreement, dated January 29, 2020, by and between Interpace Biosciences, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on January 31, 2020.

~~10.7~~		Eleventh Amendment to Lease, effective as of June 1, 2020, by and between Southport Business Park Limited Partnership and Interpace Pharma Solutions, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 9, 2020.

~~10.8*#~~		~~Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, filed herewith.~~

~~10.9*#~~		~~Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, filed herewith.~~

31.1*		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2*		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1+		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

32.2+		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

101		The following financial information from this Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Stockholders’ Equity; (iv) the Condensed Consolidated Statements of Cash Flows; and (v) the Notes to Condensed Consolidated Financial Statements.